[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 504
1. Park KK, Liu K, Hu Y, Smith PD, Wang C, Cai B, Xu B, Connolly L, Kramvis I, Sahin M, He Z: Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science; 2008 Nov 7;322(5903):963-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway.
  • The failure of axons to regenerate is a major obstacle for functional recovery after central nervous system (CNS) injury.
  • Deletion of PTEN (phosphatase and tensin homolog), a negative regulator of the mammalian target of rapamycin (mTOR) pathway, in adult retinal ganglion cells (RGCs) promotes robust axon regeneration after optic nerve injury.
  • In wild-type adult mice, the mTOR activity was suppressed and new protein synthesis was impaired in axotomized RGCs, which may contribute to the regeneration failure.
  • Thus, our results suggest the manipulation of intrinsic growth control pathways as a therapeutic approach to promote axon regeneration after CNS injury.


2. Bergler-Czop B, Lis-Swiety A, Brzezińska-Wcisło L: Scleroderma linearis: hemiatrophia faciei progressiva (Parry-Romberg syndrom) without any changes in CNS and linear scleroderma "en coup de sabre" with CNS tumor. BMC Neurol; 2009;9:39
Genetic Alliance. consumer health - Scleroderma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scleroderma linearis: hemiatrophia faciei progressiva (Parry-Romberg syndrom) without any changes in CNS and linear scleroderma "en coup de sabre" with CNS tumor.
  • CASE PRESENTATION: We present two cases of a disease: a case of a 49-year-old woman with a typical image of hemifacial atrophy, without any changes of the nervous system and a case of a 33-year-old patient with an "en coup de sabre" scleroderma and with CNS tumor.
  • In the patient diagnosed with Parry-Romberg syndrome, with Borrelia burgdoferi infection and with minor neurological symptoms, despite a four-year case history, there was a lack of proper diagnosis and treatment.In the second patient only skin changes without any neurological symptoms could be observed and only a precise neurological diagnosis revealed the presence of CNS tumor.
  • [MeSH-minor] Adult. Borrelia burgdorferi. Cerebral Ventricle Neoplasms / complications. Cerebral Ventricle Neoplasms / pathology. Diagnosis, Differential. Electromyography. Female. Humans. Lyme Disease / complications. Magnetic Resonance Imaging. Middle Aged. Neurologic Examination. Tomography, Spiral Computed. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Linear scleroderma (subtype).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 2003 Sep;30(9):1997-2004 [12966605.001]
  • [Cites] BMC Dermatol. 2001;1:9 [11741509.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Apr;18(4):751-7 [9127045.001]
  • [Cites] J Pediatr. 2005 Mar;146(3):429-31 [15756237.001]
  • [Cites] J Am Acad Dermatol. 2006 Feb;54(2):227-33 [16443052.001]
  • [Cites] Childs Nerv Syst. 2006 Apr;22(4):409-15 [16247619.001]
  • [Cites] Neurology. 2003 Sep 9;61(5):674-6 [12963760.001]
  • [Cites] Hautarzt. 2006 Oct;57(10):905-6 [16960731.001]
  • [Cites] J Am Acad Dermatol. 2007 Feb;56(2):257-63 [17147965.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Apr;29(4):714-5 [18202229.001]
  • [Cites] Pediatr Neurol. 2001 Nov;25(5):416-8 [11744320.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 May;74(5):661-4 [12700315.001]
  • [Cites] Klin Monbl Augenheilkd. 2003 Jun;220(6):427-32 [12830399.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Sep;27(8):1729-31 [16971623.001]
  • (PMID = 19635150.001).
  • [ISSN] 1471-2377
  • [Journal-full-title] BMC neurology
  • [ISO-abbreviation] BMC Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2723072
  •  go-up   go-down


3. Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski C, Goldman S, Manley PE, Bowers DC, Bendel A, Rubin J, Turner CD, Marcus KJ, Goumnerova L, Ullrich NJ, Kieran MW: Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol; 2009 Jan 20;27(3):385-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor.
  • PURPOSE: Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, with a historic median survival ranging from 6 to 11 months.
  • Based on a previous pilot series, a prospective multi-institutional trial was conducted for patients with newly diagnosed CNS ATRT.
  • Gross total resection of the primary tumor was achieved in 11 patients.
  • CONCLUSION: This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis tumor.
  • [MeSH-major] Brain Neoplasms / therapy. Rhabdoid Tumor / therapy. Teratoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Humans. Infratentorial Neoplasms. Prognosis. Prospective Studies. Supratentorial Neoplasms. Young Adult

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):235-40 [18381756.001]
  • [Cites] Radiology. 1969 Dec;93(6):1351-9 [4983156.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):332-7 [3030922.001]
  • [Cites] Pediatr Neurol. 1991 Jul-Aug;7(4):237-42 [1930413.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):258 [1637409.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):71-5 [7743242.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1013-9 [9719110.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1491-9 [15735125.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):77-84 [15803379.001]
  • [Cites] Pediatr Blood Cancer. 2005 May;44(5):478-86 [15918215.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E8 [16048294.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):97-111 [16855864.001]
  • [Cites] J Pediatr Psychol. 2007 Sep;32(8):918-25 [17522113.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2877-84 [15254056.001]
  • (PMID = 19064966.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA046274; United States / NCI NIH HHS / CA / R01 CA046274-17A2; United States / NCI NIH HHS / CA / CA46274
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2645855
  •  go-up   go-down


Advertisement
4. Badruddoja MA, Keir ST, King I, Zeidner J, Vredenburgh JJ, Muhlbaier LH, Bigner DD, Friedman HS: Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro Oncol; 2007 Jul;9(3):240-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.
  • The current study was designed to assess the activity of VNP40101M administered at a dose of 18 mg/kg daily for five days against a panel of human adult and pediatric CNS tumors growing subcutaneously or intracranially in athymic nude mice.
  • The results demonstrated statistically significant (p < 0.05) growth delays of 15.0, 8.3, 51.0, 60+, 60+, and 60+ days in subcutaneous xenografts derived from childhood glioblastoma multiforme (D-456 MG), childhood ependymoma (D-528 EP and D-612 EP), childhood medulloblastoma (D-425 MED), and adult malignant glioma (D-245 MG and D-54 MG), respectively, with corresponding tumor regressions in 10 of 10, 4 of 10, 8 of 10, 9 of 10, 9 of 10, and 10 of 10 treated mice, respectively.
  • Additional experiments conducted against subcutaneous D-245 MG xenografts by using reduced doses of 13.5 or 9.0 mg/kg daily for five days demonstrated tumor growth delays of 82.2 and 53.5 days, with corresponding tumor regressions in 8 of 9 and 9 of 10 treated mice, respectively (all values, p < 0.001), with one toxic death.
  • These findings suggest that VNP40101M is active in the treatment of a wide range of human central nervous system tumors and warrants translation to the clinic.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1994;34(2):171-4 [8194169.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2933-6 [9230204.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):123-35 [15744588.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Biochem Pharmacol. 2000 Feb 1;59(3):283-91 [10609557.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3033-8 [11306484.001]
  • [Cites] Int J Toxicol. 2002 Jan-Feb;21(1):23-38 [11936896.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Apr;53(4):288-95 [14685775.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2908-17 [15131024.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Neurosurgery. 1979 Apr;4(4):308-14 [450229.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4189-95 [3390813.001]
  • [Cites] J Neurooncol. 1994;20(2):111-20 [7807189.001]
  • (PMID = 17522334.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / 5P50-NS20023-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazines; 0 / Prodrugs; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  • [Other-IDs] NLM/ PMC1907418
  •  go-up   go-down


5. Busch SA, Horn KP, Silver DJ, Silver J: Overcoming macrophage-mediated axonal dieback following CNS injury. J Neurosci; 2009 Aug 12;29(32):9967-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overcoming macrophage-mediated axonal dieback following CNS injury.
  • Trauma to the adult CNS initiates multiple processes including primary and secondary axotomy, inflammation, and glial scar formation that have devastating effects on neuronal regeneration.
  • These data provide valuable insight into the cellular and molecular mechanisms underlying macrophage-mediated axonal retraction and demonstrate modifications that can alleviate the detrimental effects of this unfavorable phenomenon on the postlesion CNS.

  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2000 Jan 1;20(1):315-25 [10627609.001]
  • [Cites] Nat Rev Neurosci. 2003 Sep;4(9):703-13 [12951563.001]
  • [Cites] Mol Cell Neurosci. 2001 Jun;17(6):945-56 [11414785.001]
  • [Cites] J Neurosci. 2001 Jul 1;21(13):4782-8 [11425905.001]
  • [Cites] Nat Rev Neurosci. 2001 Jul;2(7):502-11 [11433375.001]
  • [Cites] Nature. 2002 Apr 11;416(6881):636-40 [11948352.001]
  • [Cites] Neuron. 2002 Jun 13;34(6):885-93 [12086637.001]
  • [Cites] Neuron. 2002 Jun 13;34(6):895-903 [12086638.001]
  • [Cites] Neuron. 2002 Jul 3;35(1):13-6 [12123603.001]
  • [Cites] J Neurosci. 2002 Sep 1;22(17):7526-35 [12196576.001]
  • [Cites] J Neurosurg. 2003 Sep;99(2 Suppl):188-97 [12956462.001]
  • [Cites] J Neurosci. 2003 Dec 3;23(35):11127-35 [14657171.001]
  • [Cites] Nat Rev Neurosci. 2003 Dec;4(12):981-90 [14682360.001]
  • [Cites] Nat Rev Neurosci. 2004 Feb;5(2):146-56 [14735117.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8786-90 [15173585.001]
  • [Cites] J Neurosci. 2004 Jul 21;24(29):6531-9 [15269264.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):617-29 [15286728.001]
  • [Cites] Circ Res. 2004 Aug 20;95(4):364-71 [15256478.001]
  • [Cites] Nature. 1984 Jun 28-Jul 4;309(5971):791-3 [6204205.001]
  • [Cites] Cell Calcium. 1993 Nov;14(10):736-45 [8131190.001]
  • [Cites] J Neuroimmunol. 1997 Feb;72(2):155-61 [9042108.001]
  • [Cites] Neuron. 1999 May;23(1):83-91 [10402195.001]
  • [Cites] J Neurosci. 1999 Jul 15;19(14):5810-22 [10407022.001]
  • [Cites] Brain. 2005 Jul;128(Pt 7):1622-33 [15800021.001]
  • [Cites] J Neurosci. 2005 Aug 31;25(35):8066-76 [16135764.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16848-52 [16275900.001]
  • [Cites] Nat Rev Neurosci. 2005 Dec;6(12):931-44 [16288297.001]
  • [Cites] J Neurosci. 2006 Apr 19;26(16):4406-14 [16624960.001]
  • [Cites] J Neurosci. 2006 Jul 12;26(28):7405-15 [16837588.001]
  • [Cites] Nat Rev Neurosci. 2006 Aug;7(8):617-27 [16858390.001]
  • [Cites] J Neurosci. 2006 Sep 27;26(39):9841-50 [17005848.001]
  • [Cites] J Neurosci. 2006 Oct 18;26(42):10856-67 [17050723.001]
  • [Cites] Curr Opin Neurobiol. 2007 Feb;17(1):120-7 [17223033.001]
  • [Cites] Dev Neurobiol. 2007 Aug;67(9):1166-82 [17514714.001]
  • [Cites] J Neurosci. 2007 Jul 25;27(30):7911-20 [17652582.001]
  • [Cites] J Neurosci. 2007 Aug 22;27(34):9169-80 [17715353.001]
  • [Cites] Exp Neurol. 2008 Feb;209(2):483-96 [17936753.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):2999-3006 [18292522.001]
  • [Cites] Exp Neurol. 2008 Apr;210(2):331-8 [18158149.001]
  • [Cites] J Neurosci. 2008 Apr 30;28(18):4613-8 [18448637.001]
  • [Cites] Nat Rev Neurosci. 2008 Jun;9(6):481-93 [18490917.001]
  • [Cites] J Neurosci. 2008 Sep 17;28(38):9330-41 [18799667.001]
  • [Cites] J Neurosci. 2002 Dec 1;22(23):10408-15 [12451140.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47461-8 [12354772.001]
  • [Cites] J Neurosci. 2003 Mar 15;23(6):2284-93 [12657687.001]
  • [Cites] Mol Cell Neurosci. 2003 Mar;22(3):383-95 [12691739.001]
  • [Cites] J Neurosci. 2001 Jan 1;21(1):92-7 [11150324.001]
  • (PMID = 19675231.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS025713-17; United States / NINDS NIH HHS / NS / R37 NS025713; United States / NINDS NIH HHS / NS / NS25713; United States / NIA NIH HHS / AG / T32 AG00271; United States / NIA NIH HHS / AG / T32 AG000271; United States / NINDS NIH HHS / NS / R01 NS025713
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aggrecans; 0 / Matrix Metalloproteinase Inhibitors; 0 / Proteoglycans; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 4.2.2.20 / Chondroitin ABC Lyase
  • [Other-IDs] NLM/ NIHMS141238; NLM/ PMC2771342
  •  go-up   go-down


6. Carson KA, Grossman SA, Fisher JD, Shaw EG: Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol; 2007 Jun 20;25(18):2601-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials.
  • The studies had similar inclusion criteria and were conducted within the New Approaches to Brain Tumor Therapy CNS Consortium.
  • RESULTS: Factors associated with an increased risk of death were increased age, lower Karnofsky performance score (KPS), initial and on-study histologies of glioblastoma multiforme (GBM), corticosteroid use, shorter time from original diagnosis to recurrence, and tumor outside frontal lobe.
  • Median survival time was poorest in non-GBM patients with KPS less than 80 or GBM patients, age 50 years, corticosteroid use (4.4 months; 95% CI, 3.6 to 5.4 months); median survival was best in patients with initial histology other than GBM with KPS 80 and tumor confined to the frontal lobe (25.7 months; 95% CI, 18.7 to 52.5), and was 7.0 months (95% CI, 6.2 to 8.0 months) for all patients.

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3260-6 [11432894.001]
  • [Cites] Neuro Oncol. 2000 Jan;2(1):29-33 [11302251.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Front Radiat Ther Oncol. 1999;33:150-7 [10549485.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):399-404 [17264335.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5174-81 [16951236.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):177-82 [15831235.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):32-40 [15701280.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2B):1303-11 [9615807.001]
  • [Cites] Acta Oncol. 1996;35 Suppl 8:123-7 [9073058.001]
  • [Cites] J Clin Epidemiol. 1995 May;48(5):675-89 [7730923.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):297-303 [12924704.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):615-9 [14628127.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):227-35 [15279715.001]
  • [Cites] Mol Ther. 2004 Nov;10(5):958-66 [15509513.001]
  • [Cites] J Clin Oncol. 1983 Jan;1(1):38-44 [6321671.001]
  • [Cites] Acta Oncol. 1989;28(1):51-5 [2539846.001]
  • [CommentIn] J Clin Oncol. 2012 Feb 10;30(5):562-3; author reply 563-4 [22215743.001]
  • (PMID = 17577040.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / CA62475
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS507874; NLM/ PMC4118746
  •  go-up   go-down


7. Bäcklund LM, Grandér D, Brandt L, Hall P, Ekbom A: Parathyroid adenoma and primary CNS tumors. Int J Cancer; 2005 Mar 1;113(6):866-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid adenoma and primary CNS tumors.
  • There are several case reports of MEN Type 1-associated central nervous system (CNS) tumors.
  • To determine if there is an association between parathyroid adenomas and CNS tumors, we used Swedish registry data to identify all individuals operated on for parathyroid adenomas between 1958-99 (n = 12,468).
  • Follow-up for the occurrence of CNS tumors in these individuals was through linkage with the Swedish Cancer Registry.
  • There were 70 observed cases of a CNS tumor diagnosed after a parathyroid adenoma, to be compared to 35 expected (standard incidence ratio [SIR] = 2.0; 95% confidence interval [CI] = 1.5-2.5).
  • These results strongly indicate an association between these tumor forms that may be genetic, environmental (such as radiation) or a combination of both.
  • [MeSH-major] Adenoma / epidemiology. Central Nervous System Neoplasms / epidemiology. Parathyroid Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasms, Second Primary / epidemiology. Registries. Retrospective Studies. Sweden / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15515018.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Crawford JR, Santi MR, Cornelison R, Sallinen SL, Haapasalo H, MacDonald TJ: Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors. J Neurooncol; 2009 Oct;95(1):49-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors.
  • The purpose is to determine the incidence of active and latent human herpesvirus-6 (HHV-6) infection in a large cohort of adult primary and recurrent CNS tumors.
  • We screened a tissue microarray (TMA) containing more than 200 adult primary and recurrent CNS tumors with known clinical information for the presence of HHV-6 DNA by in situ hybridization (ISH) and protein by immunohistochemistry (IHC).
  • One hundred six of 224 (47%) CNS tumors were positive for HHV-6 U57 Major Capsid Protein (MCP) gene by ISH compared to 0/25 non tumor control brain (P = 0.001).
  • Fourteen of 30 (47%) tumors were HHV-6 MCP positive by nested PCR compared to 0/25 non-tumor brain controls (P = 0.001), revealing HHV-6 Variant A in 6 of 14 samples.
  • HHV-6A/B early (p41) and late (gp116/64/54) antigens were detected by IHC in 66 of 277 (24%) (P = 0.003) and 84 of 282 (35%) (P = 0.002) tumors, respectively, suggesting active infection.
  • Glial tumors were 3 times more positive by IHC compared to non glial tumors for both HHV-6 gp116/64/54 (P = 0.0002) and HHV-6 p41 (P = 0.004).
  • HHV-6 early and late antigens are detected in adult primary and recurrent CNS tumors more frequently in glial tumors.
  • We hypothesize that the glial-tropic features of HHV-6 may play an important modifying role in tumor biology that warrants further investigation.
  • [MeSH-major] Antigens, Viral. Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / virology. Glioma / genetics. Glioma / virology. Herpesvirus 6, Human / isolation & purification
  • [MeSH-minor] Adult. Antigens, CD / metabolism. CD48 Antigen. Capsid Proteins / genetics. Capsid Proteins / metabolism. Humans. Survival Analysis. Viral Envelope Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1988 May 14;1(8594):1065-7 [2896909.001]
  • [Cites] J Pathol. 2002 Jul;197(3):395-402 [12115887.001]
  • [Cites] Clin Microbiol Rev. 1999 Jul;12(3):367-82 [10398670.001]
  • [Cites] J Infect Dis. 2000 Nov;182(5):1321-5 [11023456.001]
  • [Cites] J Med Virol. 2005 Jan;75(1):76-85 [15543581.001]
  • [Cites] Neurology. 2003 Nov 25;61(10):1405-11 [14638964.001]
  • [Cites] J Med Virol. 2007 Jan;79(1):45-51 [17133548.001]
  • [Cites] J Virol. 2005 Aug;79(15):9439-48 [16014907.001]
  • [Cites] Pediatrics. 2008 Sep;122(3):513-20 [18762520.001]
  • [Cites] Mult Scler. 2004 Aug;10(4):355-9 [15327029.001]
  • [Cites] J Infect Dis. 2003 May 1;187(9):1377-87 [12717618.001]
  • [Cites] Curr Infect Dis Rep. 2008 Jul;10(4):292-9 [18765102.001]
  • [Cites] Curr Infect Dis Rep. 2004 Aug;6(4):316-321 [15265461.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1545-9 [10477678.001]
  • [Cites] PLoS One. 2008 Apr 30;3(4):e2028 [18446218.001]
  • [Cites] Oncogene. 1997 Jan 23;14(3):359-67 [9018122.001]
  • [Cites] Epilepsia. 2008 Nov;49(11):1828-37 [18627418.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(6):563-6 [17637686.001]
  • [Cites] Annu Rev Med. 2000;51:423-30 [10774474.001]
  • [Cites] New Microbiol. 1999 Oct;22(4):293-300 [10555198.001]
  • [Cites] J Neurosci. 2004 May 19;24(20):4875-83 [15152048.001]
  • [Cites] Mult Scler. 1999 Oct;5(5):355-62 [10516780.001]
  • [Cites] J Neurovirol. 2003 Oct;9(5):539-50 [13129768.001]
  • [Cites] J Neurol Sci. 1995 Dec;134(1-2):184-8 [8747864.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • [Cites] Neuro Oncol. 2008 Feb;10(1):10-8 [17951512.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):539-41 [18669440.001]
  • [Cites] J Child Neurol. 2007 Nov;22(11):1260-8 [18006954.001]
  • [Cites] J Neurovirol. 1998 Oct;4(5):486-94 [9839646.001]
  • [Cites] Acta Neuropathol. 2008 Jul;116(1):79-86 [18351367.001]
  • [Cites] Clin Diagn Virol. 1996 Jun;6(1):33-40 [15566888.001]
  • [Cites] Glia. 2006 Jun;53(8):789-98 [16541415.001]
  • [Cites] J Med Virol. 2008 Apr;80(4):689-93 [18297709.001]
  • [Cites] J Med Virol. 2004 Jul;73(3):465-73 [15170644.001]
  • [Cites] Hematol Oncol. 2004 Dec;22(4):169-77 [16134192.001]
  • [Cites] J Neurol. 1997 Jul;244(7):450-4 [9266465.001]
  • [Cites] J Clin Pathol. 1999 Aug;52(8):620-3 [10645234.001]
  • [Cites] J Clin Microbiol. 2008 Aug;46(8):2700-6 [18550745.001]
  • [Cites] J Med Virol. 2001 Jan;63(1):45-51 [11130886.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):838-43 [15578071.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3347-50 [12067971.001]
  • [Cites] Brain Res. 2008 Jul 24;1221:108-14 [18565499.001]
  • [Cites] Clin Microbiol Rev. 2005 Jan;18(1):217-45 [15653828.001]
  • [Cites] J Med Virol. 1995 Sep;47(1):105-11 [8551252.001]
  • [Cites] J Med Microbiol. 2003 Jan;52(Pt 1):5-18 [12488560.001]
  • [Cites] J Infect Dis. 2006 Apr 1;193(7):912-6 [16518751.001]
  • [Cites] J Infect Dis. 2007 Feb 1;195(3):450-4 [17205485.001]
  • [Cites] J Neurovirol. 2006 Apr;12(2):90-9 [16798670.001]
  • [Cites] PLoS Med. 2007 May;4(5):e180 [17535102.001]
  • (PMID = 19424665.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K12NS052159-01A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Viral; 0 / CD48 Antigen; 0 / Capsid Proteins; 0 / Viral Envelope Proteins
  •  go-up   go-down


9. Ahuja G, Cuellar S, Choudhry I, Setty S, Yao M, Villano JL: Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy. Onkologie; 2008 Mar;31(3):119-21
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy.
  • INTRODUCTION: Locally advanced tumors in the olfactory area commonly have central nervous system (CNS) involvement and are often incurable.
  • CASE REPORT: We report the treatment of a 25-year-old male patient who presented with a large, neuroendocrine tumor arising from the ethmoid complex.
  • An endoscopic nasal biopsy demonstrated a poorly differentiated neuroendocrine tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / therapy. Ethmoid Bone / pathology. Neuroendocrine Tumors / therapy. Radiotherapy, Adjuvant. Skull Neoplasms / therapy
  • [MeSH-minor] Adult. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Humans. Male. Organization and Administration

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18322415.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


10. Lepore AC, Neuhuber B, Connors TM, Han SS, Liu Y, Daniels MP, Rao MS, Fischer I: Long-term fate of neural precursor cells following transplantation into developing and adult CNS. Neuroscience; 2006 Sep 29;142(1):287-304
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term fate of neural precursor cells following transplantation into developing and adult CNS.
  • Successful strategies for transplantation of neural precursor cells for replacement of lost or dysfunctional CNS cells require long-term survival of grafted cells and integration with the host system, potentially for the life of the recipient.
  • Few studies have examined the long-term properties of transplanted neural precursor cells in the CNS, particularly in non-neurogenic regions of the adult.
  • The aim of the present study was to extensively characterize the fate of defined populations of neural precursor cells following transplantation into the developing and adult CNS (brain and spinal cord) for up to 15 months, including integration of graft-derived neurons with the host.
  • We found that in both developing and adult CNS grafted cells showed long-term survival, morphological maturation, extensive distribution and differentiation into all mature CNS cell types (neurons, astrocytes and oligodendrocytes).
  • Graft-derived neurons also formed synapses, as identified by electron microscopy, suggesting that transplanted neural precursor cells integrated with adult CNS.
  • We did not detect tumor formation, cells did not localize to unwanted locations and no pronounced immune response was present at the graft sites.
  • The long-term stability of neuronal-restricted precursors and glial-restricted precursors and the lack of adverse effects suggest that transplantation of lineage-restricted neural precursor cells can serve as an effective and safe replacement therapy for CNS injury and degeneration.
  • [MeSH-major] Cell Differentiation / physiology. Central Nervous System / physiology. Neurons / physiology. Stem Cell Transplantation / methods. Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedFrom] Neuroscience. 2006 May 12;139(2):513-30 [16458439.001]
  • (PMID = 17120358.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS 37515; United States / NINDS NIH HHS / NS / NS24707
  • [Publication-type] Comparative Study; Corrected and Republished Article; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gangliosides; 0 / Immunosuppressive Agents; 0 / Nerve Tissue Proteins; 0 / Neural Cell Adhesion Molecules; 0 / ganglioside A2B5
  •  go-up   go-down


11. Lepore AC, Neuhuber B, Connors TM, Han SS, Liu Y, Daniels MP, Rao MS, Fischer I: Long-term fate of neural precursor cells following transplantation into developing and adult CNS. Neuroscience; 2006 May 12;139(2):513-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term fate of neural precursor cells following transplantation into developing and adult CNS.
  • Successful strategies for transplantation of neural precursor cells for replacement of lost or dysfunctional CNS cells require long-term survival of grafted cells and integration with the host system, potentially for the life of the recipient.
  • Few studies have examined the long-term properties of transplanted neural precursor cells in the CNS, particularly in non-neurogenic regions of the adult.
  • The aim of the present study was to extensively characterize the fate of defined populations of neural precursor cells following transplantation into the developing and adult CNS (brain and spinal cord) for up to 15 months, including integration of graft-derived neurons with the host.
  • We found that in both developing and adult CNS grafted cells showed long-term survival, morphological maturation, extensive distribution and differentiation into all mature CNS cell types (neurons, astrocytes and oligodendrocytes).
  • Graft-derived neurons also formed synapses, as identified by electron microscopy, suggesting that transplanted neural precursor cells integrated with adult CNS.
  • We did not detect tumor formation, cells did not localize to unwanted locations and no pronounced immune response was present at the graft sites.
  • The long-term stability of neuronal-restricted precursors and glial-restricted precursors and the lack of adverse effects suggest that transplantation of lineage-restricted neural precursor cells can serve as an effective and safe replacement therapy for CNS injury and degeneration.
  • [MeSH-major] Cell Transplantation / methods. Central Nervous System / physiology. Neurons / physiology. Stem Cells / physiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Neuroscience. 2006 Sep 29;142(1):285
  • [RepublishedIn] Neuroscience. 2006 Sep 29;142(1):287-304 [17120358.001]
  • (PMID = 16458439.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS 37515; United States / NINDS NIH HHS / NS / NS24707
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gangliosides; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, rat; 0 / Nestin; 0 / Neural Cell Adhesion Molecules; 0 / RNA, Messenger; 0 / ganglioside A2B5; EC 3.1.3.1 / Alkaline Phosphatase; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


12. Kamoshima Y, Sawamura Y, Ikeda J, Shirato H, Aoyama H: Late recurrence and salvage therapy of CNS germinomas. J Neurooncol; 2008 Nov;90(2):205-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence and salvage therapy of CNS germinomas.
  • Central nervous system (CNS) germinoma is a curable tumor and its recurrence rate after initial therapy may be approximately 10% or higher.
  • All patients had been tumor-free for at least 6 months after the initial treatment.
  • Seventeen patients (68%) were salvaged and were tumor-free at the final observation.
  • At first recurrence, 11 patients were treated using radiation therapy with or without surgery and 7 out of the 11 patients died due to the recurrent tumor.
  • On the other hand, 13 patients who received salvage chemotherapy and radiotherapy were tumor-free at the last follow-up.
  • In conclusion, late recurrence is not a rare event in patients with CNS germinoma.
  • [MeSH-major] Central Nervous System Neoplasms / prevention & control. Germinoma / prevention & control. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Child. Female. Follow-Up Studies. Humans. Male. Remission Induction. Retrospective Studies. Secondary Prevention. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5503-11 [17158535.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):66-72 [9420074.001]
  • [Cites] Int J Urol. 2005 Sep;12(9):855-8 [16201988.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):943-9 [7607968.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):857-65 [11821471.001]
  • [Cites] Pediatr Blood Cancer. 2004 Aug;43(2):126-33 [15236278.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):262-6 [9254091.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2228-36 [17019739.001]
  • [Cites] J Urol. 2005 Mar;173(3):824-9 [15711278.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):204-9 [9440744.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1934-43 [15143087.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2585-92 [10561326.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):940-4 [8039122.001]
  • [Cites] Radiology. 2001 Feb;218(2):452-6 [11161161.001]
  • [Cites] Childs Nerv Syst. 2007 Oct;23(10):1155-61 [17610071.001]
  • [Cites] Br J Neurosurg. 1999 Aug;13(4):376-81 [10616563.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):820-7 [16508636.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):520-30 [12209744.001]
  • [Cites] Eur J Cancer. 1998 Jan;34(1):104-10 [9624246.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):214-7 [15337558.001]
  • [Cites] Urol Int. 2004;73(1):84-6 [15263799.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2908-15 [8918487.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1292-7; discussion 1297-8 [10598695.001]
  • [Cites] Acta Oncol. 2006;45(4):476-83 [16760185.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Jan;28(1):36-9 [16394891.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):291-7 [3403312.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):311-6 [11767296.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1171-6 [10725628.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):933-40 [10071287.001]
  • [Cites] Am J Clin Oncol. 2007 Apr;30(2):205-10 [17414472.001]
  • [Cites] J Neurooncol. 2007 May;83(1):71-9 [17245622.001]
  • (PMID = 18604473.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kirkpatrick JP, Vredenburgh JJ, Desjardins A, Gururangan S, Peters KB, Boulton ST, Friedman AH, Friedman HS, Reardon DA: Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma. J Clin Oncol; 2009 May 20;27(15_suppl):e13007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13007 Background: Malignant glioma (MG), an incurable primary CNS tumor, is characterized by frequent aberrant activation of EGFR, VEGFR, and PDGFR.
  • METHODS: Adult recurrent MG patients with ≤ 3 prior recurrences, KPS ≥ 60% and adequate organ function were stratified based on concurrent enzyme-inducing anticonvulsant use (EIAC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. da Silva NS, Cappellano AM, Diez B, Cavalheiro S, Gardner S, Wisoff J, Kellie S, Parker R, Garvin J, Finlay J: Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study. Pediatr Blood Cancer; 2010 Mar;54(3):377-83
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study.
  • BACKGROUND: The treatment of central nervous system (CNS) germ cell tumors (GCT) remains controversial.
  • METHODS: Between January 2001 and December 2004 newly diagnosed patients with CNS GCT were treated with one of two risk-tailored chemotherapy regimens.
  • Twenty-five patients aged 4 months to 24.5 years were stratified: Regimen A consisted of 4-6 cycles of carboplatin/etoposide alternating with cyclophosphamide/etoposide for low risk (LR) localized germinoma with normal cerebrospinal fluid (CSF) and serum tumor markers.
  • Our results indicate that, at the present time, standard treatment for CNS GCT continues to include irradiation either alone or combined with chemotherapy for pure germinomas and with chemotherapy for those with MMGCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Carboplatin / adverse effects. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Infant. Male. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 20063410.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


15. Gläsker S, Klingler JH, Müller K, Würtenberger C, Hader C, Zentner J, Neumann HP, Velthoven VV: Essentials and pitfalls in the treatment of CNS hemangioblastomas and von Hippel-Lindau disease. Cent Eur Neurosurg; 2010 May;71(2):80-7
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Essentials and pitfalls in the treatment of CNS hemangioblastomas and von Hippel-Lindau disease.
  • Hemangioblastomas are rare CNS tumors, which are mostly located in the posterior fossa or spinal cord and occasionally in spinal nerves.
  • They can occur sporadically or as a component tumor of von Hippel-Lindau (VHL) disease, an autosomal dominant tumor syndrome.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Hemangioblastoma / pathology. Hemangioblastoma / surgery. Neurosurgical Procedures / methods. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / surgery. von Hippel-Lindau Disease / pathology. von Hippel-Lindau Disease / surgery
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 20229452.001).
  • [ISSN] 1868-4912
  • [Journal-full-title] Central European neurosurgery
  • [ISO-abbreviation] Cent Eur Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL: Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol; 2008 Jan 1;26(1):96-105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein biomarker identification in the CSF of patients with CNS lymphoma.
  • PURPOSE: Elucidation of the CSF proteome may yield insights into the pathogenesis of CNS disease.
  • We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions.
  • METHODS: We used a liquid chromatography/mass spectrometry-based method to differentially quantify and identify several hundred CSF proteins in CNS lymphoma and control patients.
  • ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selectively to tumor neovasculature.
  • We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in CNS lymphoma and brain metastasis.
  • [MeSH-major] Biomarkers, Tumor / cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Lymphoma / cerebrospinal fluid. Neoplasm Proteins / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antithrombin III / genetics. Antithrombin III / metabolism. Case-Control Studies. Chromatography, Liquid. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoblotting. Immunoenzyme Techniques. Leukemia, Myeloid / cerebrospinal fluid. Leukemia, Myeloid / pathology. Lymphoma, B-Cell / cerebrospinal fluid. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / cerebrospinal fluid. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / cerebrospinal fluid. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / cerebrospinal fluid. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Proteomics. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3575-82 [15284095.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):705-17, vii [16083831.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1341-9 [15970584.001]
  • [Cites] Dis Markers. 2006;22(1-2):3-26 [16410649.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37302-10 [17040907.001]
  • [Cites] Expert Rev Mol Med. 2006;8(31):1-19 [17156576.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Anal Chem. 2003 Sep 15;75(18):4818-26 [14674459.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):641-8 [11148663.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2922-7 [15131026.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):72-5 [17236490.001]
  • [CommentIn] J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4 [19332721.001]
  • (PMID = 18056677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA100291
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS612770; NLM/ PMC4134101
  •  go-up   go-down


17. Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Birch JM: Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol; 2009 Aug;11(4):403-13
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England.
  • Around 25% of all tumors in those 0-14 years of age and 9% in those 15-24 years of age involve the CNS.
  • In adults 25-84 years of age, the proportion of CNS tumors is 2%; 5-year overall survival is 10%-15%; and survivors have considerable morbidity.
  • Comprehensive up-to-date population-based incidence data on these tumors are lacking.
  • We present incidence rates for primary CNS tumors based on data derived from the high-quality national cancer registration system in England.
  • A total of 54,336 CNS tumors of malignant, benign, and uncertain behavior were registered across the whole of England from 1995 through 2003.
  • This is higher than previously reported for England because it includes nonmalignant CNS tumors and hence gives a more accurate picture of burden of disease.
  • In this article, we describe the changing patterns in the epidemiology of primary CNS tumors in these three age groups with respect to sex, tumor behavior, and histology using the current WHO classification.
  • [MeSH-major] Brain Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. England / epidemiology. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Risk Factors. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):168-74 [10634382.001]
  • [Cites] Br J Cancer. 2007 Dec 3;97(11):1588-94 [17987032.001]
  • [Cites] Am J Otol. 2000 Sep;21(5):690-4 [10993460.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1548-56 [11920513.001]
  • [Cites] Br J Neurosurg. 2002 Apr;16(2):140-5 [12046732.001]
  • [Cites] Med Pediatr Oncol. 2002 Sep;39(3):190-4 [12210449.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):61-9 [12416547.001]
  • [Cites] Br J Cancer. 2002 Nov 18;87(11):1267-74 [12439716.001]
  • [Cites] Dev Med Child Neurol. 2003 May;45(5):308-14 [12729144.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):168-78 [12816723.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):450-5 [14648713.001]
  • [Cites] Neuroepidemiology. 2004 May-Jun;23(3):101-9 [15084778.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii12-7 [15146034.001]
  • [Cites] Mayo Clin Proc. 1978 Oct;53(10):641-3 [713594.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):881-9 [4056902.001]
  • [Cites] Zentralbl Neurochir. 1987;48(2):120-3 [3673352.001]
  • [Cites] Childs Nerv Syst. 1991 Aug;7(4):177-82 [1933913.001]
  • [Cites] Am J Epidemiol. 1992 Jun 15;135(12):1349-57 [1510081.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Sep;41(3):359-64 [7893282.001]
  • [Cites] J Neurooncol. 1995;25(1):67-71 [8523091.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):827-33 [8608471.001]
  • [Cites] Neurol Med Chir (Tokyo). 1999 Jan;39(1):59-107 [10093464.001]
  • [Cites] Laryngoscope. 1999 May;109(5):736-40 [10334223.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):996-1001 [15986431.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):1-11 [16443943.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] Acta Neurochir (Wien). 2006 Aug;148(8):865-71; discussion 871 [16791430.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):2064-80 [16919771.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4754-7 [16966685.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):81-9 [17482475.001]
  • [Cites] Health Stat Q. 2007 Autumn;(35):78-83 [17894201.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1420-5 [10770176.001]
  • (PMID = 19033157.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2743220
  •  go-up   go-down


18. Morris EB, Gajjar A, Okuma JO, Yasui Y, Wallace D, Kun LE, Merchant TE, Fouladi M, Broniscer A, Robison LL, Hudson MM: Survival and late mortality in long-term survivors of pediatric CNS tumors. J Clin Oncol; 2007 Apr 20;25(12):1532-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and late mortality in long-term survivors of pediatric CNS tumors.
  • PURPOSE: To describe the pattern of survival and late mortality among contemporary long-term survivors of pediatric CNS tumor.
  • PATIENTS AND METHODS: The study population comprised 643 pediatric patients with primary CNS tumor treated at St Jude Children's Research Hospital (Memphis, TN) from 1985 to 2000 who survived > or = 5 years from diagnosis.
  • Patients were classified according to primary tumor type, location of tumor, and survival.
  • A significant difference in the survival rates according to original tumor type (P = .001) was seen.
  • Sixty-six (10%) of 643 patients experienced late mortality: 38 patients (58%) died of progressive disease while 14 patients (21%) died of second malignant tumor.
  • Twelve patients (18%), predominantly with diencephalic tumor location, died of a specific medical cause: cardiovascular disease (n = 2), cerebrovascular accident (n = 1), metabolic collapse and/or sepsis (n = 7), respiratory failure (n = 1), or shunt malfunction (n = 1).
  • CONCLUSION: Late mortality occurs in a substantial number of long-term survivors of pediatric CNS tumors and is most influenced by the initial tumor histopathology.
  • [MeSH-major] Cause of Death. Central Nervous System Neoplasms / mortality. Survivors / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Cohort Studies. Disease Progression. Disease-Free Survival. Female. Humans. Incidence. Male. Neoplasm Staging. Prognosis. Registries. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442996.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Horger M, Fenchel M, Nägele T, Moehle R, Claussen CD, Beschorner R, Ernemann U: Water diffusivity: comparison of primary CNS lymphoma and astrocytic tumor infiltrating the corpus callosum. AJR Am J Roentgenol; 2009 Nov;193(5):1384-7
Hazardous Substances Data Bank. Water .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Water diffusivity: comparison of primary CNS lymphoma and astrocytic tumor infiltrating the corpus callosum.
  • OBJECTIVE: The purpose of this study was to determine whether lymphoma and astrocytic tumor infiltrating the corpus callosum can be reliably differentiated with measurement of water diffusivity.
  • Regions of interest were drawn on apparent diffusion coefficient (ADC) maps inside the callosal tumor.
  • ADCs were normalized by calculation of the ratio between the ADC of the tumor and the ADC of an uninvolved region of corpus callosum.
  • RESULTS: The mean ADC of glioblastoma multiforme was 1.13 +/- 0.31 (SD) x 10(-3) mm(2)/s, and the mean tumor to corpus callosum ADC ratio was 1.51 +/- 0.46; of low-grade astrocytoma, 1.14 +/- 0.23 x 10(-3) mm(2)/s and 1.54 +/- 0.28; gliomatosis cerebri, 1.01 +/- 0.20 x 10(-3) mm(2)/s and 1.31 +/- 0.36; and lymphoma, 0.71 +/- 0.13 x 10(-3) mm(2)/s and 0.93 +/- 0.19.
  • The difference between the mean tumor to corpus callosum ADC ratio of lymphoma and that of all grades of astrocytoma (1.48 +/- 0.43) was statistically significant (p < 0.001).
  • The optimal ADC threshold for discriminating astrocytic tumor and lymphoma was 0.90 x 10(-3) mm(2)/s (sensitivity, 84%; specificity, 89%).
  • The optimal threshold for tumor to corpus callosum ADC ratio was 1.22 (sensitivity, 73%; specificity, 100%).
  • CONCLUSION: The water diffusivity and the ADC ratio of the tumor to normal-appearing corpus callosum of astrocytic tumor differ significantly from those of lymphoma infiltrating the corpus callosum, allowing reliable differentiation of the two types of tumor.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Corpus Callosum / pathology. Diffusion Magnetic Resonance Imaging / methods. Glioblastoma / pathology. Lymphoma / pathology. Water / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. ROC Curve. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843757.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 059QF0KO0R / Water
  •  go-up   go-down


20. Murray G, Jiménez L, Báez F, Colón-Castillo LE, Brau RH: Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico. P R Health Sci J; 2009 Dec;28(4):317-28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico.
  • INTRODUCTION: Published studies regarding the incidence of central nervous system (CNS) tumors in Puerto Rico (PR) are exceedingly rare.
  • The general understanding is that the incidence of these tumors in Puerto Rico is similar to the one found in the United States of America (USA).
  • The objective of this study is to describe the specific profile of all the CNS tumors that are surgically intervened in Puerto Rico, through the creation of a database.
  • METHODS: A retrospective analysis of all the surgical procedures from January 1, 2002 to May 31, 2006 for adult CNS tumors in Puerto Rico was performed.
  • The information was organized to form a database of all the CNS neoplasms.
  • RESULTS: A total of 1,018 procedures for CNS tumors were performed on 1,005 patients.
  • The incidence rate of surgically intervened CNS tumors in Puerto Rico is 6 per 100,000 people.
  • CNS tumors were more common in women than in men (58% vs. 42%), respectively.
  • CONCLUSIONS: Our results reflect a unique histopathological distribution of operated CNS tumors in Puerto Rico.
  • In this series, primary tumors are more common than metastatic tumors.
  • Benign histological tumors were more frequent than more malignant variants.
  • Although this study reflects only the histologically diagnosed tumors, it is headway towards diagnosing the incidence of all CNS tumors in Puerto Rico.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Puerto Rico. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999240.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


21. Engelhard HH, Corsten LA: Leptomeningeal metastasis of primary central nervous system (CNS) neoplasms. Cancer Treat Res; 2005;125:71-85
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal metastasis of primary central nervous system (CNS) neoplasms.
  • Leptomeningeal dissemination of primary CNS tumors varies widely by histologic subtype.
  • In certain tumors including medulloblastoma, ependymoma, germ cell tumors, and primary CNS lymphoma, seeding of the cerebrospinal fluid space is a critical factor in determining stage, prognosis and appropriate therapy.
  • Other tumor types, such as glioma, may have radiographic evidence of leptomeningeal metastases without clear impact on prognosis or therapy.
  • [MeSH-major] Brain Neoplasms / pathology. Central Nervous System Neoplasms / pathology. Meningeal Neoplasms / secondary
  • [MeSH-minor] Adult. Child. Humans. Incidence

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211884.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 86
  •  go-up   go-down


22. Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C, Burns DK, Bajenaru ML, Gutmann DH, Parada LF: Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development; 2005 Dec;132(24):5577-88
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.
  • The gene responsible for neurofibromatosis type 1 (NF1) encodes a tumor suppressor that functions as a negative regulator of the Ras proto-oncogene.
  • Individuals with germline mutations in NF1 are predisposed to the development of benign and malignant tumors of the peripheral and central nervous system (CNS).
  • Children with this disease suffer a high incidence of optic gliomas, a benign but potentially debilitating tumor of the optic nerve; and an increased incidence of malignant astrocytoma, reactive astrogliosis and intellectual deficits.
  • In the present study, we have sought insight into the molecular and cellular basis of NF1-associated CNS pathologies.
  • We show that mice genetically engineered to lack NF1 in CNS exhibit a variety of defects in glial cells.
  • Primary among these is a developmental defect resulting in global reactive astrogliosis in the adult brain and increased proliferation of glial progenitor cells leading to enlarged optic nerves.
  • These data point to hyperproliferative glial progenitors as the source of the optic tumors and provide a genetic model for NF1-associated astrogliosis and optic glioma.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):361-7 [10931370.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):759-67 [11005256.001]
  • [Cites] J Neurosci. 2005 Jun 8;25(23):5584-94 [15944386.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7773-9 [15520182.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):38-44 [10469435.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4450-9 [10442636.001]
  • [Cites] Neuron. 2000 May;26(2):533-41 [10839371.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1433-8 [10688783.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):557-64 [16069817.001]
  • [Cites] Development. 2000 Dec;127(24):5253-63 [11076748.001]
  • [Cites] Neuron. 2000 Oct;28(1):69-80 [11086984.001]
  • [Cites] Nature. 2001 Feb 8;409(6821):714-20 [11217860.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] Nat Rev Neurosci. 2001 Apr;2(4):287-93 [11283751.001]
  • [Cites] Neurology. 2001 Apr 10;56(7):885-90 [11294925.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):859-76 [11297510.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]
  • [Cites] Genesis. 2001 Oct;31(2):85-94 [11668683.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):112-7 [11689956.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2085-91 [11929829.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5100-13 [12077339.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] J Neurosci. 2002 Nov 1;22(21):9228-36 [12417648.001]
  • [Cites] Neuron. 2003 Mar 6;37(5):751-64 [12628166.001]
  • [Cites] J Neurosci. 2003 Aug 6;23(18):7207-17 [12904481.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8573-7 [14695164.001]
  • [Cites] Neuron. 2004 Mar 25;41(6):881-90 [15046721.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Cell. 1990 Nov 16;63(4):835-41 [2121369.001]
  • [Cites] Cell. 1990 Nov 16;63(4):851-9 [2121371.001]
  • [Cites] Neuron. 1992 Mar;8(3):415-28 [1550670.001]
  • [Cites] Dev Dyn. 1992 Nov;195(3):216-26 [1301085.001]
  • [Cites] Dev Biol. 1994 Feb;161(2):538-51 [8314000.001]
  • [Cites] Neuron. 1994 Apr;12(4):895-908 [8161459.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Genes Dev. 1994 May 1;8(9):1019-29 [7926784.001]
  • [Cites] Development. 1994 Sep;120(9):2637-49 [7956838.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jul;54(4):588-600 [7602332.001]
  • [Cites] J Cell Biol. 1995 Oct;131(2):453-64 [7593171.001]
  • [Cites] Development. 1995 Nov;121(11):3583-92 [8582272.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):862-72 [9001241.001]
  • [Cites] Ann Neurol. 1997 Feb;41(2):143-9 [9029062.001]
  • [Cites] Trends Neurosci. 1997 Dec;20(12):570-7 [9416670.001]
  • [Cites] Cell. 1998 Sep 18;94(6):703-14 [9753318.001]
  • [Cites] Brain Res. 1999 Jan 16;816(1):111-23 [9878702.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] J Neurosci. 1999 Feb 1;19(3):1049-61 [9920668.001]
  • (PMID = 16314489.001).
  • [ISSN] 0950-1991
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS052606-01; United States / NINDS NIH HHS / NS / P50 NS052606; United States / NINDS NIH HHS / NS / P50 NS052606-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurofibromin 1
  • [Other-IDs] NLM/ NIHMS149022; NLM/ PMC2760350
  •  go-up   go-down


23. Yamanaka R, Morii K, Shinbo Y, Takeuchi S, Tamura T, Hondoh H, Takahashi H, Onda K, Takahashi H, Tanaka R: Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma. Ann Hematol; 2005 Jul;84(7):447-55
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
  • The object of this study was to assess the estimation of 2- and 5-year overall survival and tumor response and the frequency and severity of treatment morbidity with a modified ProMACE-MOPP hybrid protocol in patients with primary CNS lymphoma (PCNSL).
  • Eighteen patients were followed up with neuroimaging and neuropsychological assessments for evidence of CNS toxicity.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Central Nervous System Neoplasms / therapy. Cranial Irradiation. Lymphoma / therapy. Methotrexate / administration & dosage
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Etoposide / administration & dosage. Etoposide / toxicity. Female. Humans. Leukopenia / chemically induced. Male. Mechlorethamine / administration & dosage. Mechlorethamine / toxicity. Middle Aged. Pneumonia / etiology. Pneumonia / mortality. Prednisone / administration & dosage. Prednisone / toxicity. Procarbazine / administration & dosage. Procarbazine / toxicity. Retrospective Studies. Sepsis / etiology. Sepsis / mortality. Vincristine / administration & dosage. Vincristine / toxicity

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15747120.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ProMACE-MOPP protocol
  •  go-up   go-down


24. Chen YW, Wong TT, Ho DM, Huang PI, Chang KP, Shiau CY, Yen SH: Impact of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor (single institute experience). Int J Radiat Oncol Biol Phys; 2006 Mar 15;64(4):1038-43
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor (single institute experience).
  • PURPOSE: To assess outcomes and prognostic factors in radiotherapy of pediatric central nervous system atypical teratoid/rhabdoid tumor (AT/RT).
  • METHODS AND MATERIALS: Seventeen patients with central nervous system AT/RT were retrospectively reviewed after curative radiotherapy as primary or adjuvant therapy between January 1990 and December 2003.
  • The 3 longest-surviving patients were older, underwent gross tumor removal, and completed both craniospinal and focal boost irradiation.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Rhabdoid Tumor / radiotherapy. Teratoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cranial Irradiation / methods. Disease-Free Survival. Female. Humans. Male. Multivariate Analysis. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1273; author reply 1273-4 [16798419.001]
  • (PMID = 16406394.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Riazi K, Galic MA, Kuzmiski JB, Ho W, Sharkey KA, Pittman QJ: Microglial activation and TNFalpha production mediate altered CNS excitability following peripheral inflammation. Proc Natl Acad Sci U S A; 2008 Nov 4;105(44):17151-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microglial activation and TNFalpha production mediate altered CNS excitability following peripheral inflammation.
  • We hypothesized that peripheral inflammation leads to increased neuronal excitability arising from a CNS immune response.
  • We induced inflammation in the gut by intracolonic administration of 2,4,6-trinitrobenzene sulfonic acid (TNBS) to adult male rats.
  • The TNBS-treated rats exhibited a marked, reversible inflammatory response within the hippocampus, characterized by microglial activation and increases in tumor necrosis factor alpha (TNFalpha) levels.
  • Central antagonism of TNFalpha using a monoclonal antibody or inhibition of microglial activation by i.c.v. injection of minocycline prevented the increase in seizure susceptibility.
  • Our finding of a microglia-dependent TNFalpha-mediated increase in CNS excitability provides insight into potential mechanisms underlying the disparate neurological and behavioral changes associated with chronic inflammation.
  • [MeSH-major] Central Nervous System / immunology. Colitis / immunology. Microglia / metabolism. Tumor Necrosis Factor-alpha / biosynthesis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Picryl sulfonic acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2006 Jan;43(1):154-62 [16374849.001]
  • [Cites] J Physiol. 2003 May 1;548(Pt 3):929-39 [12640019.001]
  • [Cites] Epilepsia. 2005 Dec;46(12):1955-62 [16393162.001]
  • [Cites] Nature. 2006 Apr 20;440(7087):1054-9 [16547515.001]
  • [Cites] Neurobiol Dis. 2006 Sep;23(3):689-96 [16843675.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R308-15 [16973935.001]
  • [Cites] Eur J Neurol. 2007 May;14(5):483-93 [17437605.001]
  • [Cites] Acta Biomed. 2007;78 Suppl 1:231-47 [17465337.001]
  • [Cites] Eur J Neurosci. 2007 Jun;25(12):3605-16 [17610580.001]
  • [Cites] Seizure. 2007 Oct;16(7):636-44 [17570689.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Oct;293(4):G711-8 [17673544.001]
  • [Cites] Ann N Y Acad Sci. 2007 Oct;1113:173-7 [17656565.001]
  • [Cites] Brain Behav Immun. 2008 Jan;22(1):114-23 [17919885.001]
  • [Cites] Nat Rev Neurosci. 2008 Jan;9(1):46-56 [18073775.001]
  • [Cites] Brain Behav Immun. 2008 Mar;22(3):301-11 [17951027.001]
  • [Cites] Eur J Neurosci. 2008 Feb;27(3):644-53 [18279317.001]
  • [Cites] Neurosci Lett. 2008 Jun 6;437(3):188-93 [18420346.001]
  • [Cites] Brain Res. 1999 Sep 11;841(1-2):70-7 [10546989.001]
  • [Cites] Infect Immun. 1999 Dec;67(12):6364-8 [10569751.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Feb;292(2):497-504 [10640285.001]
  • [Cites] J Neurochem. 2000 Feb;74(2):457-71 [10646496.001]
  • [Cites] Brain Res. 2000 Mar 17;859(1):15-20 [10720610.001]
  • [Cites] Int Rev Immunol. 2000;19(1):51-62 [10723677.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11534-9 [11016948.001]
  • [Cites] J Neurophysiol. 2001 Mar;85(3):1246-56 [11247993.001]
  • [Cites] Brain Res Bull. 2001 Mar 1;54(4):443-53 [11306198.001]
  • [Cites] J Neurosci. 2001 Apr 15;21(8):2580-8 [11306611.001]
  • [Cites] Br J Anaesth. 2001 Jul;87(1):3-11 [11460811.001]
  • [Cites] Glia. 2002 Nov;40(2):218-31 [12379909.001]
  • [Cites] Brain Behav Immun. 2002 Oct;16(5):596-601 [12401474.001]
  • [Cites] J Neurosci. 2003 Jan 1;23(1):52-63 [12514201.001]
  • [Cites] Brain Behav Immun. 2003 Feb;17(1):13-9 [12615045.001]
  • [Cites] Brain Behav Immun. 2003 Apr;17(2):69-85 [12676570.001]
  • [Cites] Neuroscience. 2003;122(4):1073-80 [14643773.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Mar;19(3):270-7 [14748873.001]
  • [Cites] Neurosci Lett. 2004 May 6;361(1-3):254-7 [15135941.001]
  • [Cites] Neurobiol Dis. 2004 Jun;16(1):190-201 [15207276.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Sep;310(3):1216-25 [15082752.001]
  • [Cites] Eur J Pharmacol. 2004 Oct 1;500(1-3):399-411 [15464048.001]
  • [Cites] J Neurophysiol. 1987 Jun;57(6):1911-24 [3037040.001]
  • [Cites] Gastroenterology. 1989 Mar;96(3):795-803 [2914642.001]
  • [Cites] J Neurophysiol. 1991 Apr;65(4):771-85 [1675671.001]
  • [Cites] Epilepsy Res. 1991 Apr;8(3):171-89 [1907909.001]
  • [Cites] Pharmacol Biochem Behav. 1993 Feb;44(2):397-402 [8383342.001]
  • [Cites] Am J Physiol. 1994 Apr;266(4 Pt 1):G560-7 [8178994.001]
  • [Cites] Epilepsy Res. 1995 Feb;20(2):137-50 [7750510.001]
  • [Cites] Neuroscience. 1995 Apr;65(3):815-26 [7609880.001]
  • [Cites] Br J Surg. 1995 Nov;82(11):1479-82 [8535797.001]
  • [Cites] Trends Neurosci. 1996 Aug;19(8):312-8 [8843599.001]
  • [Cites] J Auton Nerv Syst. 1998 Aug 27;73(1):38-45 [9808369.001]
  • [Cites] Infect Immun. 1999 Mar;67(3):1455-60 [10024595.001]
  • [Cites] J Neurosci. 1999 Jun 15;19(12):5054-65 [10366638.001]
  • [Cites] J Neurosci. 2005 Mar 23;25(12):3219-28 [15788779.001]
  • [Cites] Neurogastroenterol Motil. 2005 Jun;17(3):433-46 [15916631.001]
  • [Cites] Ann Neurol. 2005 Jun;57(6):804-12 [15852477.001]
  • [Cites] Dig Dis Sci. 2005 Sep;50(9):1669-76 [16133967.001]
  • [Cites] Cytokine. 2005 Oct 21;32(2):85-93 [16213154.001]
  • [Cites] Epilepsia. 2005 Nov;46(11):1724-43 [16302852.001]
  • [Cites] J Neurosci. 2008 Jul 2;28(27):6904-13 [18596165.001]
  • [Cites] Brain Behav Immun. 2008 Aug;22(6):797-803 [18495419.001]
  • [Cites] Epilepsia. 2005 Dec;46(12):1906-13 [16393156.001]
  • (PMID = 18955701.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Tumor Necrosis Factor-alpha; 8T3HQG2ZC4 / Trinitrobenzenesulfonic Acid
  • [Other-IDs] NLM/ PMC2579393
  •  go-up   go-down


26. Moravan M, Segal BM: Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology; 2009 Jan 27;72(4):337-40
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil.
  • OBJECTIVE: To describe the effects of the anti-tumor necrosis factor neutralizing antibody, infliximab, and the antiproliferative immunosuppressant, mycophenolate mofetil, in refractory neurosarcoidosis.
  • METHODS: We treated patients with biopsy-proven sarcoidosis and CNS involvement, who had failed treatment with steroids, with infliximab (5 mg/kg on weeks 0, 2, and 6, and then every 6-8 weeks thereafter).
  • A positive treatment response was attained irrespective of location or distribution of CNS involvement by sarcoidosis (dural/leptomeningeal based vs intraparenchymal; cord vs brain; single lesion vs multifocal).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Central Nervous System Diseases / drug therapy. Mycophenolic Acid / analogs & derivatives. Sarcoidosis / drug therapy
  • [MeSH-minor] Adult. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Infliximab. Male. Middle Aged. Treatment Outcome


27. Rezanko T, Tunakan M, Kahraman A, Sucu HK, Gelal F, Akkol I: Primary rhabdoid tumor of the brain in an adult. Neuropathology; 2006 Feb;26(1):57-61
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary rhabdoid tumor of the brain in an adult.
  • Rhabdoid tumor (RT) is an uncommon childhood neoplasm that typically arises within the kidney.
  • Since its description in 1978, several cases of primary extrarenal RT, including a CNS localization, have been reported.
  • The first case in the CNS was reported in 1985 and was defined as "rhabdoid tumor" initially, and was classified as grade IV in the most recent classification of the World Health Organization under the term of "atypical teratoid/rhabdoid tumor".
  • Nearly 200 cases of atypical teratoid/rhabdoid tumor of the CNS have been reported to date, most of them occurring in childhood.
  • This tumor, which was composed purely of rhabdoid cells with no additional primitive neuroectodermal, epithelial and mesenchymal components, was in a 27-year-old male patient.
  • In conclusion, RT should be considered also in the differential diagnosis of intracerebral neoplasms of adult patients.
  • [MeSH-major] Brain Neoplasms / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Meningioma / pathology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16521480.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Schumann M, Kiewe P, Hartlieb S, Neumann M, Schilling A, Koch HC, Thiel E, Korfel A: Diffuse leukoencephalopathy and brain edema: unusual presentations of CNS relapse of acute myeloid leukemia. J Neuroimaging; 2010 Apr;20(2):198-200
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse leukoencephalopathy and brain edema: unusual presentations of CNS relapse of acute myeloid leukemia.
  • An isolated CNS relapse is rarely seen in acute myeloid leukemia.
  • In conjunction with normal findings in the peripheral blood-count with differential and the bone marrow examination a diagnosis of an isolated CNS relapse of the AML was made.
  • The case highlights the relevance of the CNS as a pharmacologic "sanctuary" for tumor cells in patients that on prior treatments have not received intrathecal chemotherapy or chemotherapeutics that cross the blood-brain barrier.
  • [MeSH-minor] Adult. Humans. Male. Recurrence


29. Kiewe P, Loddenkemper C, Anagnostopoulos I, Reinwald M, Thiel E, Korfel A: High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma. Neuro Oncol; 2007 Apr;9(2):96-102
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma.
  • In patients with parenchymal brain masses of uncertain origin responsive to corticosteroids, primary CNS lymphoma (PCNSL) should be considered.
  • PCNSL is a rare but aggressive brain tumor that is highly sensitive to high-dose methotrexate (HDMTX)-based chemotherapy.
  • [MeSH-major] Brain Neoplasms / drug therapy. Central Nervous System Neoplasms / drug therapy. Lymphoma / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Biopsy. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Recurrence. Stereotaxic Techniques

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1999 Jul;43(3):231-6 [10563428.001]
  • [Cites] Clin Imaging. 2004 Jul-Aug;28(4):261-70 [15246475.001]
  • [Cites] Eur J Endocrinol. 2000 Apr;142(4):365-72 [10754478.001]
  • [Cites] Mol Pathol. 2000 Aug;53(4):194-200 [11040942.001]
  • [Cites] J R Soc Med. 2000 Nov;93(11):586-8 [11198690.001]
  • [Cites] Neurology. 2001 May 22;56(10):1313-8 [11376180.001]
  • [Cites] J Neurol. 2001 Jun;248(6):451-68 [11499635.001]
  • [Cites] Neurology. 2001 Aug 14;57(3):393-6 [11515505.001]
  • [Cites] Neurology. 2002 Feb 12;58(3):390-6 [11839837.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):354-62 [12186464.001]
  • [Cites] Neurology. 2002 Sep 10;59(5):762-4 [12221174.001]
  • [Cites] Neurology. 1988 Jul;38(7):1153-5 [3386836.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2461-5 [3179963.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Jul-Aug;10(4):725-9 [2505501.001]
  • [Cites] Br J Neurosurg. 1990;4(5):407-15 [2261103.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):9-17 [1572835.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Jul-Aug;13(4):1207-13 [1636538.001]
  • [Cites] J Nucl Med. 1993 Apr;34(4):567-75 [8455072.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):188-95 [8027800.001]
  • [Cites] Oncology (Williston Park). 1995 Jan;9(1):63-71; discussion 71, 75-6, 78 [7718442.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):102-5 [8558135.001]
  • [Cites] Ophthalmology. 1996 Mar;103(3):521-8 [8600431.001]
  • [Cites] Clin Imaging. 1996 Jul-Sep;20(3):171-7 [8877168.001]
  • [Cites] Neuroradiology. 1996 Aug;38(6):560-5 [8880719.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] Cancer. 1998 May 1;82(9):1749-55 [9576298.001]
  • [Cites] J Neurol Sci. 2004 Dec 15;227(1):85-9 [15546596.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):173-80 [15690135.001]
  • [Cites] Br J Haematol. 2005 Mar;128(5):616-24 [15725082.001]
  • [Cites] Neurol Sci. 2004 Nov;25 Suppl 4:S361-3 [15727234.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):169-77 [15925998.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] QJM. 2005 Sep;98(9):643-54 [16040668.001]
  • [Cites] Neurology. 2005 Oct 11;65(7):1057-65 [16217059.001]
  • [Cites] Arch Neurol. 2005 Nov;62(11):1673-80 [16286539.001]
  • [Cites] Clin Neurol Neurosurg. 2007 Jan;109(1):92-101 [16644103.001]
  • [Cites] Neurosci Lett. 2003 Feb 27;338(2):119-22 [12566167.001]
  • [Cites] Neurosci Lett. 2003 May 22;342(3):163-6 [12757890.001]
  • [Cites] Br J Radiol. 2004 Feb;77(914):153-6 [15010391.001]
  • [Cites] Arq Neuropsiquiatr. 1999 Dec;57(4):921-6 [10683680.001]
  • (PMID = 17301290.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC1871672
  •  go-up   go-down


30. Barth RF, Kaur B: Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol; 2009 Sep;94(3):299-312
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.
  • In this review we will describe eight commonly used rat brain tumor models and their application for the development of novel therapeutic and diagnostic modalities.
  • The C6, 9L and T9 gliomas were induced by repeated injections of methylnitrosourea (MNU) to adult rats.
  • The 9L gliosarcoma has been used widely and has provided important information relating to brain tumor biology and therapy.
  • Both of these tumors arose in Fischer rats and can be immunogenic in syngeneic hosts, a fact that must be taken into consideration when used in therapy studies, especially if survival is the endpoint.
  • The RG2 and F98 gliomas were both chemically induced by administering ethylnitrosourea (ENU) to pregnant rats, the progeny of which developed brain tumors that subsequently were propagated in vitro and cloned.
  • The CNS-1 glioma was induced by administering MNU to a Lewis rat.
  • This tumor has been used for a variety of studies to evaluate new therapeutic modalities.
  • The Avian Sarcoma Virus (ASV) induced tumors, and a continuous cell line derived from one of them designated RT-2, have been useful for studies in which de novo tumor induction is an important requirement.
  • These tumors also are immunogenic and this limits their usefulness for therapy studies.
  • [MeSH-major] Brain Neoplasms. Glioma
  • [MeSH-minor] Animals. Cell Line, Tumor / pathology. Disease Models, Animal. Gene Expression Regulation, Neoplastic. Mice. Rats

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2004 Nov;101(5):826-31 [15540922.001]
  • [Cites] Mol Ther. 2004 Dec;10(6):1071-84 [15564139.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8561-76 [15623640.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):341-50 [15671565.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2533-43 [15728459.001]
  • [Cites] Mol Cancer. 2005;4(1):12 [15762988.001]
  • [Cites] Brain Res Mol Brain Res. 2005 Apr 27;135(1-2):93-103 [15857672.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3475-84 [15867250.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3821-7 [15897582.001]
  • [Cites] J Neurooncol. 2005 May;72(3):209-15 [15937642.001]
  • [Cites] Brain Res. 2005 Jun 14;1047(1):56-64 [15893739.001]
  • [Cites] Am J Pathol. 2005 Aug;167(2):565-76 [16049340.001]
  • [Cites] J Neurosurg. 2005 Jan;102(1 Suppl):53-8 [16206734.001]
  • [Cites] Neurosurg Focus. 2005 Oct 15;19(4):E1 [16241103.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):603-11 [16338098.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):52-9 [16432162.001]
  • [Cites] J Neurosurg. 2006 Jan;104(1):118-28 [16509155.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):133-48 [17874037.001]
  • [Cites] Neurochem Res. 2007 Dec;32(12):2235-42 [17701349.001]
  • [Cites] Free Radic Biol Med. 2008 Jan 1;44(1):63-72 [18045548.001]
  • [Cites] J Natl Cancer Inst. 2007 Dec 5;99(23):1768-81 [18042934.001]
  • [Cites] J Neurooncol. 2008 Jan;86(1):13-21 [17611717.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):883-91 [18245552.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):320-9 [18240929.001]
  • [Cites] Phys Med Biol. 2008 Feb 21;53(4):861-78 [18263945.001]
  • [Cites] Int J Immunopathol Pharmacol. 2008 Jan-Mar;21(1):227-31 [18336750.001]
  • [Cites] Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1977 Aug 15;89(3):273-95 [198983.001]
  • [Cites] J Neurosurg. 1979 Mar;50(3):298-304 [217977.001]
  • [Cites] Acta Neuropathol. 1980;51(1):23-31 [7435138.001]
  • [Cites] J Neurosurg. 1980 Dec;53(6):808-15 [7003068.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Sep;18(9):891-5 [6891332.001]
  • [Cites] J Neuropathol Exp Neurol. 1983 Mar;42(2):122-35 [6600780.001]
  • [Cites] J Neuropathol Exp Neurol. 1984 Jul;43(4):426-38 [6610726.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5276-81 [3019523.001]
  • [Cites] Cancer. 1987 Jan 15;59(2):266-70 [3026604.001]
  • [Cites] Ann Neurol. 1987 Sep;22(3):300-5 [3118762.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2373-8 [2015600.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2430-7 [2015604.001]
  • [Cites] J Clin Neurosci. 2008 May;15(5):545-51 [18378459.001]
  • [Cites] J Neurooncol. 2008 May;88(1):1-9 [18228115.001]
  • [Cites] Neuroimage. 2008 Apr 1;40(2):973-83 [18441552.001]
  • [Cites] J Neurosurg. 2008 May;108(5):972-8 [18447715.001]
  • [Cites] J Chemother. 2008 Apr;20(2):253-62 [18467254.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Jun;35(6):1192-203 [18264706.001]
  • [Cites] Toxicol Lett. 2008 Jun 10;179(1):29-33 [18485629.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5508-11 [18632599.001]
  • [Cites] Neuro Oncol. 2008 Jun;10(3):292-9 [18430796.001]
  • [Cites] J Cereb Blood Flow Metab. 2008 Aug;28(8):1431-9 [18414496.001]
  • [Cites] Brain Res. 2008 Aug 28;1227:198-206 [18602898.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2008 Jul-Aug;44(7):280-9 [18594936.001]
  • [Cites] J Neurooncol. 2008 Oct;90(1):19-24 [18594766.001]
  • [Cites] Eur J Pharm Biopharm. 2008 Sep;70(1):66-74 [18555675.001]
  • [Cites] Cancer Gene Ther. 2008 Oct;15(10):685-92 [18535615.001]
  • [Cites] Neurol Res. 2008 Jun;30(5):511-7 [18953742.001]
  • [Cites] NMR Biomed. 2008 Nov;21(10):1043-56 [18615861.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):530-6 [19147017.001]
  • [Cites] Eur J Radiol. 2009 Apr;70(1):180-9 [18541399.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):326-33 [10659021.001]
  • [Cites] IEEE Trans Biomed Eng. 2000 Feb;47(2):259-65 [10721633.001]
  • [Cites] Clin Exp Metastasis. 1992 Sep;10(5):345-50 [1505124.001]
  • [Cites] J Neurooncol. 1991 Dec;11(3):185-97 [1823340.001]
  • [Cites] Int J Cancer. 1992 Sep 30;52(3):409-13 [1399117.001]
  • [Cites] Cancer Res. 1993 Jan 1;53(1):176-82 [8416743.001]
  • [Cites] Science. 1993 Jan 1;259(5091):94-7 [8418502.001]
  • [Cites] J Neurosurg. 1993 Nov;79(5):729-35 [8410252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Mar 30;28(5):1067-77 [8175391.001]
  • [Cites] J Neurooncol. 1994;19(3):259-68 [7807177.001]
  • [Cites] J Neurooncol. 1994;22(3):191-200 [7760095.001]
  • [Cites] J Surg Oncol. 1995 Jun;59(2):105-9 [7776650.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):607-14 [7669569.001]
  • [Cites] Leukemia. 1995 Oct;9 Suppl 1:S106-12 [7475300.001]
  • [Cites] Int J Cancer. 1995 Sep 15;62(6):767-71 [7558428.001]
  • [Cites] Hum Gene Ther. 1995 Nov;6(11):1467-76 [8573619.001]
  • [Cites] Cancer Lett. 1997 May 1;115(1):81-90 [9097982.001]
  • [Cites] Invasion Metastasis. 1996;16(3):107-15 [9186546.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):275-7 [9293462.001]
  • [Cites] J Neurooncol. 1998 Jan;36(1):91-102 [9525831.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):2020-8 [9581848.001]
  • [Cites] Hum Gene Ther. 1999 Jan 1;10(1):95-101 [10022534.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3861-5 [10463570.001]
  • [Cites] Cancer Gene Ther. 2004 Nov;11(11):721-32 [15475879.001]
  • [Cites] Pathobiology. 1999 Jul-Aug;67(4):202-6 [10738182.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):993-9 [10871746.001]
  • [Cites] Cancer Gene Ther. 2000 Jun;7(6):879-84 [10880018.001]
  • [Cites] Cancer Gene Ther. 2000 Jun;7(6):947-53 [10880027.001]
  • [Cites] J Neurooncol. 2000;46(3):231-40 [10902854.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):22695-703 [10801887.001]
  • [Cites] Neurosurgery. 2000 Oct;47(4):993-9; discussion 999-1000 [11014444.001]
  • [Cites] Cancer Gene Ther. 2001 Jan;8(1):3-8 [11219491.001]
  • [Cites] Neurol Res. 2001 Jun;23(4):359-66 [11428516.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):37-47 [11451201.001]
  • [Cites] Histol Histopathol. 2001 Jul;16(3):735-44 [11510963.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7056-9 [11585735.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):275-87 [11718260.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):1-12 [11949821.001]
  • [Cites] Gene Ther. 2002 May;9(9):584-91 [11973634.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):143-8 [11995815.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Jun;301(3):838-51 [12023511.001]
  • [Cites] Med Oncol. 2002;19(1):1-9 [12025885.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):725-35 [12152787.001]
  • [Cites] Gene Ther. 2002 Sep;9(17):1139-45 [12170377.001]
  • [Cites] Cancer Lett. 2003 Mar 20;192(1):97-107 [12637158.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1083-93 [12651601.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):17-22 [12659666.001]
  • [Cites] J Neurooncol. 2003 Mar-Apr;62(1-2):61-74 [12749703.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3195-201 [12810648.001]
  • [Cites] J Neurooncol. 2003 May;63(1):1-7 [12814248.001]
  • [Cites] Ann Neurol. 2003 Sep;54(3):388-92 [12953273.001]
  • [Cites] Cell Immunol. 2003 Oct;225(2):113-21 [14698145.001]
  • [Cites] Gene Ther. 2004 Jan;11(2):161-9 [14712300.001]
  • [Cites] Gene Ther. 2004 Jan;11(2):214-23 [14712306.001]
  • [Cites] Mol Ther. 2004 Feb;9(2):282-91 [14759812.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2317-23 [15059878.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jul;146(7):731-4 [15197617.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5187-201 [15297423.001]
  • [Cites] Science. 1968 Jul 26;161(3839):370-1 [4873531.001]
  • [Cites] J Cell Physiol. 1970 Jun;75(3):329-39 [4988781.001]
  • [Cites] J Neurosurg. 1971 Mar;34(3):310-23 [4323142.001]
  • [Cites] J Neurosurg. 1971 Mar;34(3):335-40 [5547317.001]
  • [Cites] Cancer Res. 1973 May;33(5):976-86 [4703128.001]
  • [Cites] J Med. 1975;6(3-4):249-59 [1059719.001]
  • [Cites] J Natl Cancer Inst. 1975 Nov;55(5):1177-87 [1206744.001]
  • [Cites] Am J Pathol. 1976 Apr;83(1):149-76 [179328.001]
  • [Cites] Can J Neurol Sci. 2006 Feb;33(1):86-91 [16583728.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E25 [16709031.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):989-98 [16741309.001]
  • [Cites] J Neurosci. 2006 Jun 21;26(25):6781-90 [16793885.001]
  • [Cites] J Neurooncol. 2006 Aug;79(1):9-17 [16575532.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5288-97 [17000661.001]
  • [Cites] NMR Biomed. 2006 Dec;19(8):1035-42 [16894643.001]
  • [Cites] Childs Nerv Syst. 2006 Dec;22(12):1519-25 [17021732.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):149-62 [16941073.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1260-8 [17317838.001]
  • [Cites] J Magn Reson. 2007 May;186(1):150-5 [17303454.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2728-37 [17473206.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4541-4 [17510377.001]
  • [Cites] Mol Ther. 2007 Jul;15(7):1373-81 [17457322.001]
  • [Cites] Stem Cells. 2007 Jul;25(7):1645-53 [17412894.001]
  • [Cites] Behav Brain Res. 2007 Aug 22;182(1):42-50 [17572515.001]
  • [Cites] Mol Cancer Ther. 2007 Aug;6(8):2290-302 [17699724.001]
  • [Cites] Neoplasia. 2007 Jul;9(7):546-55 [17710157.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5195-201 [17726137.001]
  • [Cites] Magn Reson Med. 2007 Sep;58(3):454-62 [17763344.001]
  • [Cites] Can J Neurol Sci. 2007 Aug;34(3):296-306 [17803026.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):191-202 [17557137.001]
  • (PMID = 19381449.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA150153; United States / NINDS NIH HHS / NS / R01 NS064607; United States / NINDS NIH HHS / NS / R21 NS056203; United States / NINDS NIH HHS / NS / K01 NS059575; United States / NINDS NIH HHS / NS / K01 NS059575-02; United States / NINDS NIH HHS / NS / R01 NS064607-01; United States / NINDS NIH HHS / NS / R21 NS056203-02
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 149
  • [Other-IDs] NLM/ NIHMS127810; NLM/ PMC2730996
  •  go-up   go-down


31. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ: Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol; 2010 Sep 20;28(27):4221-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
  • PURPOSE: To estimate the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetic properties of lapatinib, a selective epidermal growth factor receptor (EGFR) and ERBB2 inhibitor, in children with refractory or recurrent CNS malignancies.
  • Expression of the four ERBB receptors and downstream signaling elements in tumor tissue was evaluated by immunohistochemistry.
  • Frequent, high-level expression of activated (phosphorylated) EGFR and ERBB2 receptors and downstream signal intermediates were observed in tumors, particularly in ependymomas that displayed prolonged stable disease on lapatinib therapy.
  • CONCLUSION: Lapatinib is well tolerated in children with recurrent CNS malignancies, with rash, diarrhea, and fatigue identified as DLTs.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Central Nervous System Neoplasms / drug therapy. Protein Kinase Inhibitors / administration & dosage. Quinazolines / administration & dosage
  • [MeSH-minor] Administration, Oral. Adolescent. Child. Child, Preschool. Diarrhea / chemically induced. Exanthema / chemically induced. Fatigue / chemically induced. Female. Humans. Infant. Male. Maximum Tolerated Dose. Phosphorylation. Receptor, Epidermal Growth Factor / analysis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, ErbB-2 / analysis. Receptor, ErbB-2 / antagonists & inhibitors. Steroids / therapeutic use. Treatment Outcome. United States. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Jan;65(2):353-61 [19499221.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6255-63 [12214266.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3054-64 [12374672.001]
  • [Cites] Mol Cancer Ther. 2001 Dec;1(2):85-94 [12467226.001]
  • [Cites] Lancet Oncol. 2003 Jul;4(7):397-406 [12850190.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3620-4 [14506149.001]
  • [Cites] Mol Cell. 2003 Sep;12(3):541-52 [14527402.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):984-93 [14970185.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):317-28 [15093539.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11 [15158434.001]
  • [Cites] Oncologist. 2004;9 Suppl 3:10-5 [15163842.001]
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1165-72 [2566907.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5305-13 [15955900.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 2;831(1-2):169-75 [16364699.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1630-9 [16452222.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 [16829981.001]
  • [Cites] Trends Cell Biol. 2006 Dec;16(12):649-56 [17085050.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2733-43 [17192538.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3137-43 [17634493.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3397-8 [17635950.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3753-8 [17704424.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1993-9 [18421051.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):286-97 [18544443.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4484-90 [18628463.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4921-7 [18794549.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1452-9 [19228746.001]
  • [Cites] J Biopharm Stat. 2009;19(3):437-55 [19384687.001]
  • [Cites] Clin Pharmacol Ther. 2000 Oct;68(4):356-66 [11061575.001]
  • (PMID = 20713864.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA129541; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCI NIH HHS / CA / U01CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / Steroids; 0VUA21238F / lapatinib; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2953974
  •  go-up   go-down


32. Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisäkk P, Ransohoff RM, Hofbauer M, Farina C, Derfuss T, Hartle C, Newcombe J, Hohlfeld R, Meinl E: Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain; 2006 Jan;129(Pt 1):200-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.
  • We report that immunohistologically CXCL12 was constitutively expressed in CNS parenchyma on blood vessel walls.
  • Quantitative PCR demonstrated that CXCL13 was produced in actively demyelinating multiple sclerosis lesions, but not in chronic inactive lesions or in the CNS of subjects who had no neurological disease.
  • The strong linkage of CXCL13 to immune cells and immunoglobulin levels in CSF suggests that this is one of the factors that attract and maintain B and T cells in inflamed CNS lesions.
  • [MeSH-major] Central Nervous System / immunology. Chemokines / cerebrospinal fluid. Multiple Sclerosis / immunology. Up-Regulation
  • [MeSH-minor] Acute Disease. Adult. B-Lymphocytes / immunology. Case-Control Studies. Cells, Cultured. Chemokine CXCL12. Chemokine CXCL13. Chemokines, CXC / cerebrospinal fluid. Chemotaxis, Leukocyte. Enzyme-Linked Immunosorbent Assay / methods. Female. Flow Cytometry. Humans. Immunoglobulins / immunology. Immunohistochemistry / methods. Interferon-gamma / immunology. Interleukin-1 / immunology. Interleukin-4 / immunology. Lymphocyte Activation. Male. Middle Aged. Polymerase Chain Reaction / methods. T-Lymphocytes / immunology. Tumor Necrosis Factor-alpha / immunology

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280350.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS38667
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / CXCL13 protein, human; 0 / Chemokine CXCL12; 0 / Chemokine CXCL13; 0 / Chemokines; 0 / Chemokines, CXC; 0 / Immunoglobulins; 0 / Interleukin-1; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


33. Santagata S, Hornick JL, Ligon KL: Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am J Surg Pathol; 2006 Dec;30(12):1613-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG.
  • Expression of NANOG has been detected in fetal germ cells and in gonadal germ cell tumors.
  • To assess the diagnostic utility of NANOG in central nervous system (CNS) germ cell tumors, we analyzed its expression by immunohistochemistry in a series of 12 CNS germinomas and compared its expression with other stem cell markers.
  • Strong nuclear expression of NANOG was demonstrated in >90% of the tumor cells in all cases.
  • NANOG was not detected in tumor types frequently considered in the differential diagnosis of CNS germinoma: pineoblastoma, primitive neuroectodermal tumors, medulloblastoma, lymphoma, pituitary adenoma, atypical teratoid/rhabdoid tumor, Langerhans cell histiocytosis, and gliomas.
  • These findings demonstrate that NANOG is a sensitive and specific marker of CNS germinoma.
  • Compared with other currently used markers, NANOG may have superior diagnostic characteristics and can facilitate identification of germinomas in minute surgical biopsies commonly obtained from these tumors.
  • These findings also suggest a potential biologic role for NANOG in maintenance of CNS germinoma.
  • [MeSH-major] Brain Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Germinoma / metabolism. Homeodomain Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Alkaline Phosphatase / metabolism. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Child. HMGB Proteins / metabolism. Humans. Isoenzymes / metabolism. Octamer Transcription Factor-3 / metabolism. SOXB1 Transcription Factors. Transcription Factors / metabolism

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122519.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS047213
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / HMGB Proteins; 0 / Homeodomain Proteins; 0 / Isoenzymes; 0 / NANOG protein, human; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Transcription Factors; 0 / germ-cell AP isoenzyme; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


34. Davies NW, Brown LJ, Gonde J, Irish D, Robinson RO, Swan AV, Banatvala J, Howard RS, Sharief MK, Muir P: Factors influencing PCR detection of viruses in cerebrospinal fluid of patients with suspected CNS infections. J Neurol Neurosurg Psychiatry; 2005 Jan;76(1):82-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing PCR detection of viruses in cerebrospinal fluid of patients with suspected CNS infections.
  • The likelihood of central nervous system (CNS) infection was classified as likely, possible, or unlikely.
  • Of episodes likely to be CNS viral infections, 30% were PCR positive compared to 5% categorised as unlikely.
  • Enteroviruses and HSV were found predominantly in the likely CNS viral infection group, whereas EBV was found mainly in the unlikely group.
  • [MeSH-major] Central Nervous System Viral Diseases / diagnosis. Enterovirus / isolation & purification. Herpesviridae / isolation & purification. JC Virus / isolation & purification. Polymerase Chain Reaction
  • [MeSH-minor] Adolescent. Adult. Animals. Cerebrospinal Fluid / parasitology. Cerebrospinal Fluid / virology. Child. Child, Preschool. Enterovirus Infections / diagnosis. Female. Herpesviridae Infections / diagnosis. Humans. Infant. Male. Polyomavirus Infections / diagnosis. Predictive Value of Tests. Toxoplasma / isolation & purification. Toxoplasmosis / diagnosis. Tumor Virus Infections / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 1994 May;169(5):1138-41 [8169409.001]
  • [Cites] Lancet. 1993 Aug 14;342(8868):398-401 [8101902.001]
  • [Cites] J Infect Dis. 1995 Apr;171(4):857-63 [7706811.001]
  • [Cites] Arch Neurol. 1999 Oct;56(10):1215-9 [10520937.001]
  • [Cites] Clin Infect Dis. 1995 Apr;20(4):842-8 [7795083.001]
  • [Cites] Scand J Infect Dis Suppl. 1996;100:41-5 [9163024.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Oct;61(4):339-45 [8890768.001]
  • [Cites] Lancet. 1997 Feb 1;349(9048):313-7 [9024374.001]
  • [Cites] Clin Infect Dis. 1997 Jul;25(1):86-91 [9243040.001]
  • [Cites] Clin Diagn Virol. 1997 Aug;8(2):83-104 [9316731.001]
  • [Cites] Neurology. 1998 Mar;50(3):693-7 [9521258.001]
  • [Cites] Neurology. 1998 Aug;51(2):554-9 [9710034.001]
  • [Cites] Clin Infect Dis. 1999 Oct;29(4):803-6 [10589893.001]
  • [Cites] Ann Rheum Dis. 2000 May;59(5):342-6 [10784515.001]
  • [Cites] J Clin Microbiol. 2000 Aug;38(8):3061-7 [10921978.001]
  • [Cites] J Clin Microbiol. 2001 Sep;39(9):3390-2 [11526187.001]
  • [Cites] J Clin Virol. 2002 Jul;25 Suppl 1:S59-70 [12091083.001]
  • [Cites] Clin Infect Dis. 2002 Aug 15;35(4):414-9 [12145725.001]
  • [Cites] Ann Neurol. 2002 Nov;52(5):543-8 [12402250.001]
  • [Cites] Clin Infect Dis. 2003 Jul 1;37(1):1-6 [12830402.001]
  • [Cites] J Clin Virol. 2003 Oct;28(2):175-85 [12957188.001]
  • [Cites] Clin Infect Dis. 2004 Jun 1;38(11):1629-32 [15156453.001]
  • [Cites] Scand J Infect Dis. 1975;7(4):233-7 [1209167.001]
  • [Cites] Lancet. 1984 Sep 29;2(8405):707-11 [6148470.001]
  • [Cites] Lancet. 1986 May 3;1(8488):989-91 [2422512.001]
  • [Cites] J Infect Dis. 1987 Jan;155(1):38-44 [3025307.001]
  • [Cites] Nature. 1989 May 18;339(6221):237-8 [2716852.001]
  • [Cites] JAMA. 1989 Jul 14;262(2):234-9 [2544743.001]
  • [Cites] Pediatrics. 1993 Aug;92(2):206-11 [8337018.001]
  • [CommentIn] J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):10 [15607987.001]
  • (PMID = 15608000.001).
  • [ISSN] 0022-3050
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1739313
  •  go-up   go-down


35. Ekstein D, Ben-Yehuda D, Slyusarevsky E, Lossos A, Linetsky E, Siegal T: CSF analysis of IgH gene rearrangement in CNS lymphoma: relationship to the disease course. J Neurol Sci; 2006 Aug 15;247(1):39-46
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CSF analysis of IgH gene rearrangement in CNS lymphoma: relationship to the disease course.
  • PURPOSE: To assess whether clonal IgH genes in CSF of patients with CNS lymphoma correlates with the disease course.
  • METHODS: Seventy-three CSF specimens from 32 patients (27 with primary CNS lymphoma and 5 with an isolated parenchymal CNS relapse of systemic lymphoma) were examined.
  • CNS disease was defined as active when leptomeningeal and/or parenchymal brain involvement was evident on neuroimaging.
  • Patients were considered to have a complete response when imaging confirmed absence of a tumor mass or leptomeningeal seeding.
  • The PCR study has high specificity and positive results are indicative for the presence of active disease, even when the tumor seems confined to the brain parenchyma.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Gene Rearrangement. Immunoglobulin Heavy Chains / cerebrospinal fluid. Immunoglobulin Heavy Chains / genetics. Lymphoma / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. False Negative Reactions. False Positive Reactions. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16678210.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


36. Gutenberg A, Schulten HJ, Gunawan B, Ludwig HC, Brück W, Larsen J, Rohde V: CNS tumor 22 years after spinal neuroblastoma IV: diagnostic dilemma between recurrence and secondary malignancy. Pediatr Neurosurg; 2009;45(1):61-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS tumor 22 years after spinal neuroblastoma IV: diagnostic dilemma between recurrence and secondary malignancy.
  • We present the very unusual case of a young woman suffering from a brain tumor 22 years after a stage IV spinal neuroblastoma as an infant, demonstrating the difficulties of differentiating late neuroblastoma relapse from secondary supratentorial primitive neuroectodermal tumor (sPNET).
  • Lacking specific immunohistochemical features, the first cerebral tumor at the age of 21 was regarded as sPNET, and we pursued a therapeutic approach consisting of neurosurgical resection as well as irradiation and high-dose alkylator-based chemotherapy according to the HIT2000 protocol.
  • Moreover, the lack of PNET-specific translocations (EWS/FLI1 gene fusion) in both brain tumors as well as the development of hepatic metastases was more compatible with the diagnosis of a very late relapse 22 years after initial stage IV spinal neuroblastoma.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Neuroblastoma / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Adult. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Genetic Markers. Humans. Immunohistochemistry. Infant. Magnetic Resonance Imaging. Neoplasm Staging. Time Factors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258732.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


37. Neuwelt EA, Guastadisegni PE, Várallyay P, Doolittle ND: Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. AJNR Am J Neuroradiol; 2005 Feb;26(2):258-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery.
  • We hypothesized that this would also be true in primary CNS lymphoma (PCNSL) patients who attained a complete response (CR) after treatment with chemotherapy and osmotic blood-brain barrier disruption (BBBD).
  • We hypothesized that cognitive function loss measured after tissue diagnosis but before BBBD-enhanced chemotherapy could be correlated with brain changes visualized by imaging, whereas a correlation would not be present after therapy if the patient attained a complete tumor response, analogous to the findings in children.
  • METHODS: Sixteen primary CNS lymphoma patients were followed after CR (no enhancing tumor) by using a methotrexate-based regimen.
  • Zone I was defined as enhancing tumor, and zone II as surrounding abnormal MR T2 signal intensity or low-attenuation CT.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / diagnosis. Brain Neoplasms / drug therapy. Cognition / drug effects. Lymphoma / diagnosis. Lymphoma / drug therapy. Magnetic Resonance Imaging. Methotrexate / administration & dosage. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Blood-Brain Barrier. Child. Female. Humans. Male. Middle Aged. Neuropsychological Tests. Remission Induction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJNR Am J Neuroradiol. 2005 Feb;26(2):205-6 [15709113.001]
  • (PMID = 15709122.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS 33618; United States / NINDS NIH HHS / NS / NS 34608; United States / NINDS NIH HHS / NS / R01 NS 44687
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


38. Jahnke K, Hummel M, Korfel A, Burmeister T, Kiewe P, Klasen HA, Müller HH, Stein H, Thiel E: Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol; 2006 Oct 10;24(29):4754-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes.
  • PURPOSE: To search for subclinical systemic disease in bone marrow and peripheral blood in patients with primary CNS lymphoma (PCNSL) to elucidate whether extracerebral relapse may represent a sequel of initial occult systemic disease rather than true extracerebral spread.
  • RESULTS: Identical dominant PCR products were found in bone marrow aspirates, blood samples, and tumor biopsy specimens of two patients, indicating that the same tumor cell population is present in the CNS and in extracerebral sites.
  • An oligoclonal IgH rearrangement pattern was found in the tumor specimen of two other patients, whereas bone marrow and blood samples demonstrated the same dominant PCR products.
  • [MeSH-major] Bone Marrow Neoplasms / diagnosis. Brain Neoplasms / diagnosis. Immunoglobulin Heavy Chains / genetics. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow / chemistry. Female. Gene Rearrangement. Humans. Male. Middle Aged. Neoplasm Staging / methods. Polymerase Chain Reaction. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966685.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


39. Shenkier TN, Blay JY, O'Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJ, Ponzoni M, O'Brien P, Rubenstein J, Connors JM: Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol; 2005 Apr 1;23(10):2233-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group.
  • PURPOSE: To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL).
  • Univariate and multivariate analyses were conducted for age (</= 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the CNS (no v yes), and methotrexate (MTX) use in the primary treatment (yes v no).
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Child. Child, Preschool. Cohort Studies. Female. Health Status. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800313.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


40. Tu PH, Giannini C, Judkins AR, Schwalb JM, Burack R, O'Neill BP, Yachnis AT, Burger PC, Scheithauer BW, Perry A: Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol; 2005 Aug 20;23(24):5718-27
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma.
  • PURPOSE: Although rare overall, marginal zone B-cell lymphoma (MZBCL) is the most common primary low-grade CNS lymphoma reported in the literature.
  • The aim of this study is to elucidate the biology and genetic features of this unusual tumor.
  • PATIENTS AND METHODS: Fifteen CNS MZBCLs were studied clinically, pathologically, and genetically, including fluorescent in situ hybridization analyses with commercially available MALT1 and IgH break-apart and centromere 3, 7, 12, and 18 probes.
  • RESULTS: CNS MZBCLs preferentially affect middle-aged women (female-to-male ratio, 4:1), with 93% presenting as dural-based masses mimicking meningioma.
  • Like MZBCLs outside of the CNS, they consisted of CD20+, CD3- small B lymphocytes with varying degrees of plasmacytic differentiation and predominantly kappa light-chain restriction (78%).
  • CONCLUSION: Our data suggest that intracranial MZBCL is an indolent primary CNS lymphoma that typically presents as a meningioma-like dural-based mass.
  • Trisomy 3, but not MALT1 or IgH translocation, is a common genetic abnormality that may contribute to the pathogenesis of this CNS lymphoma.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 3. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Meningioma / pathology. Middle Aged. Translocation, Genetic. Trisomy

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16009945.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Talos F, Abraham A, Vaseva AV, Holembowski L, Tsirka SE, Scheel A, Bode D, Dobbelstein M, Brück W, Moll UM: p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis. Cell Death Differ; 2010 Dec;17(12):1816-29
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis.
  • In both embryonic and adult neurogenesis, p73 has a critical role in maintaining an adequate neurogenic pool by promoting self-renewal and proliferation and inhibiting premature senescence of neural stem and early progenitor cells.
  • Thus, products of the p73 gene locus are essential maintenance factors in the central nervous system, whose broad action stretches across the entire differentiation arch from stem cells to mature postmitotic neurons.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Mar 2;404(6773):99-103 [10716451.001]
  • [Cites] Cell Stem Cell. 2009 Jul 2;5(1):64-75 [19570515.001]
  • [Cites] J Neurosci. 2001 Sep 15;21(18):7153-60 [11549726.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] J Neurosci. 2002 Nov 15;22(22):9800-9 [12427836.001]
  • [Cites] J Comp Neurol. 2004 Feb 9;469(3):311-24 [14730584.001]
  • [Cites] Development. 2004 Mar;131(6):1211-20 [14960496.001]
  • [Cites] Development. 2004 Aug;131(15):3805-19 [15240551.001]
  • [Cites] Mol Cancer Res. 2004 Jul;2(7):371-86 [15280445.001]
  • [Cites] J Comp Neurol. 2004 Oct 25;478(4):359-78 [15384070.001]
  • [Cites] J Neurosci. 2004 Oct 13;24(41):9174-84 [15483136.001]
  • [Cites] Science. 1992 Mar 27;255(5052):1707-10 [1553558.001]
  • [Cites] Brain Res Mol Brain Res. 1995 Apr;29(2):263-72 [7609614.001]
  • [Cites] Nat Genet. 1995 Jun;10(2):175-80 [7663512.001]
  • [Cites] Curr Biol. 1995 Aug 1;5(8):931-6 [7583151.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1994;59:67-73 [7587128.001]
  • [Cites] Mamm Genome. 1997 Oct;8(10):711-3 [9321461.001]
  • [Cites] Curr Opin Neurobiol. 1999 Feb;9(1):135-41 [10072370.001]
  • [Cites] Cell. 1999 Mar 5;96(5):701-12 [10089885.001]
  • [Cites] J Neurosci. 2004 Nov 3;24(44):9878-87 [15525772.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):867-74 [15471900.001]
  • [Cites] Nat Neurosci. 2005 Jun;8(6):709-15 [15917835.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Oct;6(10):777-88 [16314867.001]
  • [Cites] J Comp Neurol. 2006 Jul 1;497(1):88-100 [16680766.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 23;103(21):8233-8 [16702546.001]
  • [Cites] Curr Pharm Biotechnol. 2007 Jun;8(3):141-5 [17584087.001]
  • [Cites] Mol Cell. 2007 Aug 17;27(4):647-59 [17707235.001]
  • [Cites] Development. 2008 Feb;135(3):541-57 [18171687.001]
  • [Cites] Dev Biol. 2008 May 1;317(1):246-59 [18353302.001]
  • [Cites] Stem Cells. 2008 Apr;26(4):988-96 [18218818.001]
  • [Cites] Genes Dev. 2008 Oct 1;22(19):2677-91 [18805989.001]
  • [Cites] J Neurosci. 2008 Oct 22;28(43):11089-102 [18945916.001]
  • [Cites] Curr Top Dev Biol. 2009;87:149-74 [19427519.001]
  • [Cites] Cell Death Differ. 2009 Aug;16(8):1108-17 [19300453.001]
  • [Cites] Development. 2009 Oct;136(19):3289-99 [19736324.001]
  • [Cites] Nat Neurosci. 2009 Oct;12(10):1248-56 [19734891.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16871-6 [19805388.001]
  • [Cites] PLoS One. 2009;4(11):e7784 [19907659.001]
  • [Cites] J Neurosci. 2009 Nov 18;29(46):14394-407 [19923274.001]
  • [Cites] Genes Dev. 2010 Mar 15;24(6):549-60 [20194434.001]
  • [Cites] Science. 2000 Jul 14;289(5477):304-6 [10894779.001]
  • (PMID = 21076477.001).
  • [ISSN] 1476-5403
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS042168; United States / NCI NIH HHS / CA / CA093853-10; United States / NCI NIH HHS / CA / CA93853; United States / NIGMS NIH HHS / GM / T32 GM007518; United States / NCI NIH HHS / CA / R01 CA093853; United States / NCI NIH HHS / CA / R01 CA093853-10; United States / NINDS NIH HHS / NS / NS42168
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Receptors, Notch; 0 / SOXB1 Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  • [Other-IDs] NLM/ NIHMS338733; NLM/ PMC3260880
  •  go-up   go-down


42. Hisaoka T, Morikawa Y, Komori T, Sugiyama T, Kitamura T, Senba E: Characterization of TROY-expressing cells in the developing and postnatal CNS: the possible role in neuronal and glial cell development. Eur J Neurosci; 2006 Jun;23(12):3149-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of TROY-expressing cells in the developing and postnatal CNS: the possible role in neuronal and glial cell development.
  • A member of the tumor necrosis factor receptor superfamily, TROY, is expressed in the CNS of embryonic and adult mice.
  • [MeSH-major] Central Nervous System. Neuroglia / physiology. Neurons / physiology. Receptors, Tumor Necrosis Factor / metabolism

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820005.001).
  • [ISSN] 0953-816X
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / Microtubule-Associated Proteins; 0 / Msi1h protein, mouse; 0 / Mtap2 protein, mouse; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nes protein, rat; 0 / Nestin; 0 / RNA-Binding Proteins; 0 / Receptors, Tumor Necrosis Factor; 0 / Tnfrsf19 protein, mouse; 9061-61-4 / Nerve Growth Factor
  •  go-up   go-down


43. Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL: Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer; 2010 Jul 15;55(1):42-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation.
  • BACKGROUND: The purpose of this study was to evaluate a reduced irradiation dose strategy for newly diagnosed primary central nervous system (CNS) germinomas.
  • Initial tumor markers for beta-human chorionic gonadotrophin (HCGbeta) and alpha-fetoprotein (AFP) were evaluated in serum and lumbar cerebrospinal fluid (CSF).
  • RESULTS: Eighteen of 20 patients are without evidence of residual or recurrent tumor.
  • Both relapsing patients were subsequently determined to harbor malignant non-germinomatous germ cell tumor (NGGCT).
  • CONCLUSION: Chemotherapy followed by reduced dose whole ventricular and local boost irradiation appears to be effective in patients with localized pure CNS germinoma with evidence of preservation of neurocognitive function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Central Nervous System Neoplasms / therapy. Germinoma / therapy. Neoplasms, Germ Cell and Embryonal / therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / adverse effects. Carboplatin / therapeutic use. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Dose-Response Relationship, Radiation. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Young Adult. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20222020.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


44. Doolittle ND, Jahnke K, Belanger R, Ryan DA, Nance RW Jr, Lacy CA, Tyson RM, Haluska M, Hedrick NA, Varallyay C, Neuwelt EA: Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma; 2007 Sep;48(9):1712-20
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.
  • There was good uptake of Indium-111 ibritumomab tiuxetan in tumor on SPECT scan after 48 h.
  • Estimated radiation doses to brain around and distant from tumor were within safe limits.
  • After Ytrium-90 ibritumomab tiuxetan there was CR in enhancing tumor where the BBB was leaky, but lesions occurred in other brain regions, where the BBB was intact during Yttrium-90 ibritumomab tiuxetan infusion.
  • Imaging and dosimetry with Indium-111 ibritumomab tiuxetan and efficacy with Yttrium-90 ibritumomab tiuxetan suggest the need for future enhanced CNS delivery when using monoclonal or radiolabeled antibodies, as intravenous delivery alone may provide modest clinical benefit due to limited BBB permeability.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy. Radioimmunotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Aged. Blood-Brain Barrier. Carboplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Indium Radioisotopes / therapeutic use. Male. Methotrexate / administration & dosage. Middle Aged

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786706.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS33618; United States / NINDS NIH HHS / NS / NS34608; United States / NINDS NIH HHS / NS / NS44687
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Indium Radioisotopes; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


45. Chu LC, Eberhart CG, Grossman SA, Herman JG: Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer; 2006 Nov 15;119(10):2487-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing of multiple genes in primary CNS lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is an increasingly common tumor that has not been extensively examined for changes in promoter region methylation.
  • We examined 14 tumor suppressor genes in 25 cases of PCNSL using methylation-specific PCR.
  • Methylation of DAPK, p16(INK) (4a) or MGMT was found in 96% of the tumors, suggesting simple marker strategies to detect circulating methylated DNA in serum that might facilitate early tumor detection.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Epigenesis, Genetic. Gene Silencing. Genes, Tumor Suppressor. Lymphoma / genetics
  • [MeSH-minor] Adult. Aged. DNA Methylation. DNA, Neoplasm / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Promoter Regions, Genetic


46. Ahmed Z, Mazibrada G, Seabright RJ, Dent RG, Berry M, Logan A: TACE-induced cleavage of NgR and p75NTR in dorsal root ganglion cultures disinhibits outgrowth and promotes branching of neurites in the presence of inhibitory CNS myelin. FASEB J; 2006 Sep;20(11):1939-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TACE-induced cleavage of NgR and p75NTR in dorsal root ganglion cultures disinhibits outgrowth and promotes branching of neurites in the presence of inhibitory CNS myelin.
  • After binding, central nervous system (CNS) myelin-derived axon growth inhibitory ligands, the Nogo-66 receptor (NgR), complexes with LINGO-1 and either the low-affinity neurotrophin receptor (p75(NTR)) or TROY to initiate growth cone collapse via a Rho-A inhibitory signaling pathway and/or Ca(2+)-dependent activation of epidermal growth factor receptor (EGFR) through an unknown signaling pathway.
  • We have shown that axon growth through CNS myelin is disinhibited after neurotrophic factor administration by 1) initiating intramembranous proteolysis (RIP) of p75(NTR), leading to cleavage of the extracellular (p75(ECD)) and intracellular domains (p75(ICD)) by alpha- and gamma-secretase, respectively, thereby paralyzing inhibitory signaling;.
  • Here, we report that TNF-alpha converting enzyme (TACE) (a disintegrin and metalloproteinase 17, ADAM17) induces disinhibition of FGF2-stimulated neurite outgrowth of dorsal root ganglion neurons (DRGN) cultured in the presence of a predetermined concentration of inhibitory CNS myelin-derived ligands.
  • After addition of TACE (which has alpha-secretase activity) to mitotically arrested adult rat mixed DRG cultures, we demonstrate 1) NgR(ECD) shedding;.
  • 4) reduced EGFR phosphorylation; and 5) increased FGF2-stimulated DRGN neurite outgrowth and branching in the presence of CNS myelin-derived inhibitory ligands.
  • Thus, TACE-induced cleavage of NgR and RIP of p75(NTR) abrogates axon growth inhibitory signaling, thereby disinhibiting CNS axon/neurite growth.
  • [MeSH-minor] Animals. Cells, Cultured. Central Nervous System / physiology. Fibroblast Growth Factor 2 / pharmacology. GPI-Linked Proteins. Immunohistochemistry. Rats. Rats, Sprague-Dawley

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16849393.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 065920
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Myelin Proteins; 0 / Receptor, Nerve Growth Factor; 0 / Receptors, Cell Surface; 0 / Rtn4r protein, rat; 103107-01-3 / Fibroblast Growth Factor 2; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase
  •  go-up   go-down


47. Fliessbach K, Helmstaedter C, Urbach H, Althaus A, Pels H, Linnebank M, Juergens A, Glasmacher A, Schmidt-Wolf IG, Klockgether T, Schlegel U: Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology; 2005 Apr 12;64(7):1184-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study.
  • BACKGROUND: Combined radio- and chemotherapy for primary CNS lymphoma (PCNSL) is associated with a considerable risk of long-term neurotoxicity.
  • OBJECTIVE: To assess the impact of the tumor itself and its treatment with high-dose MTX-based chemotherapy on long-term cognition and QOL in patients with PCNSL.
  • CONCLUSION: In patients with primary CNS lymphoma (PCNSL) treated with a methotrexate (MTX)-based chemotherapy, no gross cognitive decline has to be expected as a long-term treatment effect.
  • Nevertheless, a substantial fraction of patients with PCNSL retain cognitive deficits as a residual symptom of the tumor.
  • [MeSH-major] Brain / drug effects. Brain Neoplasms / drug therapy. Cognition Disorders / chemically induced. Cognition Disorders / diagnosis. Lymphoma / drug therapy. Methotrexate / adverse effects
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / adverse effects. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nerve Fibers, Myelinated / drug effects. Nerve Fibers, Myelinated / pathology. Neuropsychological Tests. Prospective Studies. Psychomotor Performance / drug effects. Quality of Health Care. Time. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15824344.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


48. Watts JC, Drisaldi B, Ng V, Yang J, Strome B, Horne P, Sy MS, Yoong L, Young R, Mastrangelo P, Bergeron C, Fraser PE, Carlson GA, Mount HT, Schmitt-Ulms G, Westaway D: The CNS glycoprotein Shadoo has PrP(C)-like protective properties and displays reduced levels in prion infections. EMBO J; 2007 Sep 5;26(17):4038-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The CNS glycoprotein Shadoo has PrP(C)-like protective properties and displays reduced levels in prion infections.
  • The cellular prion protein, PrP(C), is neuroprotective in a number of settings and in particular prevents cerebellar degeneration mediated by CNS-expressed Doppel or internally deleted PrP ('DeltaPrP').
  • Here we demonstrate Sprn expression and Sho protein in the adult CNS.
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line, Tumor. Cerebellum / metabolism. GPI-Linked Proteins. Hippocampus / metabolism. Mice. Molecular Sequence Data. Protein Binding


49. Kuhnert F, Mancuso MR, Shamloo A, Wang HT, Choksi V, Florek M, Su H, Fruttiger M, Young WL, Heilshorn SC, Kuo CJ: Essential regulation of CNS angiogenesis by the orphan G protein-coupled receptor GPR124. Science; 2010 Nov 12;330(6006):985-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Essential regulation of CNS angiogenesis by the orphan G protein-coupled receptor GPR124.
  • The orphan G protein-coupled receptor (GPCR) GPR124/tumor endothelial marker 5 is highly expressed in central nervous system (CNS) endothelium.
  • Here, we show that complete null or endothelial-specific GPR124 deletion resulted in embryonic lethality from CNS-specific angiogenesis arrest in forebrain and neural tube.
  • Conversely, GPR124 overexpression throughout all adult vascular beds produced CNS-specific hyperproliferative vascular malformations.
  • Our results demonstrate CNS-specific angiogenesis regulation by an endothelial receptor and illuminate functions of the poorly understood adhesion GPCR subfamily.
  • Further, the functional tropism of GPR124 marks this receptor as a therapeutic target for CNS-related vascular pathologies.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Guide to Pharmacology. gene/protein/disease-specific - Adhesion Class GPCRs - overview and references .
  • Guide to Pharmacology. gene/protein/disease-specific - ADGRA2 - data and references .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2005 Jan;132(1):165-76 [15576410.001]
  • [Cites] Cell. 1998 Nov 13;95(4):507-19 [9827803.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):932-6 [16355210.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):34179-88 [16982628.001]
  • [Cites] Circ Res. 2007 Feb 2;100(2):174-90 [17272819.001]
  • [Cites] Genesis. 2008 Feb;46(2):74-80 [18257043.001]
  • [Cites] Nat Neurosci. 2008 Apr;11(4):429-39 [18344991.001]
  • [Cites] Lab Chip. 2008 Aug;8(8):1292-9 [18651071.001]
  • [Cites] Science. 2008 Nov 21;322(5905):1247-50 [19023080.001]
  • [Cites] Lymphat Res Biol. 2008;6(3-4):173-80 [19093790.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):641-6 [19129494.001]
  • [Cites] Genes Dev. 2009 Oct 1;23(19):2272-7 [19797767.001]
  • [Cites] Pediatr Res. 2010 Jan;67(1):1-8 [19816235.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):670-7 [10537105.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6649-55 [11559528.001]
  • [Cites] Development. 2002 Jun;129(12):2891-903 [12050137.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Feb 14;301(3):725-34 [12565841.001]
  • [Cites] Methods Mol Med. 2003;89:385-99 [12958435.001]
  • [Cites] J Cell Biol. 2003 Sep 15;162(6):1111-22 [12975353.001]
  • [Cites] Thromb Haemost. 2004 Mar;91(3):595-605 [14983237.001]
  • [Cites] Development. 2004 Apr;131(7):1503-13 [14998923.001]
  • [Cites] Science. 2004 May 28;304(5675):1338-40 [15060285.001]
  • [Cites] Neurobiol Dis. 2004 Jun;16(1):1-13 [15207256.001]
  • [Cites] Dev Dyn. 2004 Nov;231(3):503-9 [15376331.001]
  • [Cites] J Anat. 1989 Jun;164:85-92 [2606797.001]
  • [Cites] Nature. 1996 Apr 4;380(6573):435-9 [8602241.001]
  • [Cites] Nature. 1996 Apr 4;380(6573):439-42 [8602242.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3058-63 [9096345.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3155-61 [15626744.001]
  • (PMID = 21071672.001).
  • [ISSN] 1095-9203
  • [Journal-full-title] Science (New York, N.Y.)
  • [ISO-abbreviation] Science
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS052830; United States / NINDS NIH HHS / NS / 1R01NS064517; United States / NIH HHS / OD / 1DP2 OD006477; United States / NCI NIH HHS / CA / T32 CA009302; United States / NHLBI NIH HHS / HL / HL074267-02; United States / NINDS NIH HHS / NS / R21 NS058600; United States / NHLBI NIH HHS / HL / R01 HL074267-02; United States / NCI NIH HHS / CA / CA095654-01; United States / NINDS NIH HHS / NS / R01NS27713; United States / NINDS NIH HHS / NS / 1R01NS052830; United States / NINDS NIH HHS / NS / R01 NS027713; United States / NINDS NIH HHS / NS / 1R21 NS058600; United States / NINDS NIH HHS / NS / R01 NS052830-01; United States / NHLBI NIH HHS / HL / R01 HL074267; United States / NINDS NIH HHS / NS / R01 NS064517-02; United States / NINDS NIH HHS / NS / P01NS44155; United States / NIGMS NIH HHS / GM / GM07365; United States / NCI NIH HHS / CA / R01 CA095654; United States / NHLBI NIH HHS / HL / 1R01HL074267; United States / NINDS NIH HHS / NS / R21 NS070153; United States / NINDS NIH HHS / NS / R01 NS064517; United States / NINDS NIH HHS / NS / NS052830-01; United Kingdom / Medical Research Council / / G0501711; United States / NCI NIH HHS / CA / R01 CA095654-01; United States / NIH HHS / OD / DP2 OD006477; United States / NINDS NIH HHS / NS / NS064517-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPR124 protein, mouse; 0 / Glucose Transporter Type 1; 0 / Receptors, G-Protein-Coupled; 0 / Slc2a1 protein, mouse
  • [Other-IDs] NLM/ NIHMS296076; NLM/ PMC3099479
  •  go-up   go-down


50. Rodríguez D, Cheung MC, Housri N, Quinones-Hinojosa A, Camphausen K, Koniaris LG: Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005). J Surg Res; 2009 Oct;156(2):340-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005).
  • BACKGROUND: Determine the role of surgery and radiation therapy for patients with malignant CNS ependymomas.
  • Univariate analysis demonstrated that age, gender, ethnicity, primary tumor site, WHO grade and surgical resection were significant predictors of improved survival for ependymoma patients.
  • Multivariate analysis identified that a WHO grade III tumor, male gender, patient age, intracranial tumor locations and failure to undergo surgical resection were independent predictors of poorer outcomes.
  • For partially resected tumors, radiation therapy provides significant survival benefit.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Central Nervous System Neoplasms / surgery. Ependymoma / radiotherapy. Ependymoma / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. SEER Program. Treatment Outcome. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577759.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Mandal A, Poddar MK: Long-term caffeine consumption reverses tumor-induced suppression of the innate immune response in adult mice. Planta Med; 2008 Dec;74(15):1779-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term caffeine consumption reverses tumor-induced suppression of the innate immune response in adult mice.
  • Caffeine (1,3,7-trimethylxanthine), the active principle alkaloid of coffee ( Coffea arabica) and tea ( Camellia sinensis) possesses a restraining effect on tumor-induced suppression of the specific immune response in adult mice.
  • The present study deals with the effect of long-term consumption of caffeine in the development of Ehrlich ascites carcinoma (EAC) cells in adult Swiss female mice, in relation to the innate immune response and tumor growth.
  • Although the consumption of caffeine alone for more than 12 consecutive days did not affect the innate immune response parameters, continuation of its treatment following intraperitoneal EAC cell inoculation not only reduced the IN VIVO tumor growth but also reduced/restored the EAC cell-induced suppression of the innate immune response.
  • These results suggest that caffeine may inhibit IN VIVO tumor growth through reduction of the cancer cell-induced suppression of the innate immune response.
  • CNS:central nervous system EAC:Ehrlich ascites carcinoma ESR:erythrocyte sedimentation rate GABA:gamma-aminobutyric acid Hb:hemoglobin HPA:hypothalamic-pituitary-adrenal HPG:hypothalamic-pituitary-gonadal PCV:packed cell volume RBC:red blood cell WBC:white blood cell.
  • [MeSH-major] Caffeine / therapeutic use. Camellia sinensis. Carcinoma, Ehrlich Tumor / drug therapy. Coffea. Immunity, Innate / drug effects. Immunologic Factors / therapeutic use. Phytotherapy

  • MedlinePlus Health Information. consumer health - Caffeine.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19016405.001).
  • [ISSN] 0032-0943
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Immunologic Factors; 3G6A5W338E / Caffeine
  •  go-up   go-down


52. Maza S, Kiewe P, Munz DL, Korfel A, Hamm B, Jahnke K, Thiel E: First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro Oncol; 2009 Aug;11(4):423-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
  • Most patients with primary CNS lymphoma (PCNSL) relapse after primary therapy.
  • Anti-CD20 immunotherapy has expanded treatment options in systemic B-cell lymphoma; however, its use is limited by reconstitution of the blood-brain barrier after tumor shrinkage.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Central Nervous System Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Male. Middle Aged. Prognosis. Prospective Studies. Remission Induction. Survival Rate. Tissue Distribution. Yttrium Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1999 Jul;43(3):249-57 [10563431.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] Eur J Cancer. 1991;27(11):1356-61 [1835848.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Eur J Haematol. 2005 Apr;74(4):348-52 [15777348.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2528-34 [17932895.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1710-1 [15972281.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):53-8 [16283435.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Nov;7(3):236-8 [17229341.001]
  • [Cites] J Neurooncol. 2007 Jul;83(3):291-3 [17245621.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1712-20 [17786706.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • (PMID = 19060176.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  • [Other-IDs] NLM/ PMC2743222
  •  go-up   go-down


53. Okano H: Strategies toward CNS-regeneration using induced pluripotent stem cells. Genome Inform; 2009 Oct;23(1):217-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies toward CNS-regeneration using induced pluripotent stem cells.
  • Surprisingly, SNSs derived from c-Myc minus iPS cells generated without drug selection showed robust tumorigenesis, in spite of their potential to contribute adult chimeric mice without tumor formation.
  • [MeSH-major] Central Nervous System / physiology. Pluripotent Stem Cells / cytology. Regeneration

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20180278.001).
  • [ISSN] 0919-9454
  • [Journal-full-title] Genome informatics. International Conference on Genome Informatics
  • [ISO-abbreviation] Genome Inform
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


54. Cady FM, O'Neill BP, Law ME, Decker PA, Kurtz DM, Giannini C, Porter AB, Kurtin PJ, Johnston PB, Dogan A, Remstein ED: Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol; 2008 Oct 10;26(29):4814-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.
  • PURPOSE: Primary CNS lymphoma (PCNSL) is an aggressive lymphoma but clinically validated biologic markers that can predict natural history to tailor treatment according to risk are lacking.
  • Several genetic changes including BCL6 rearrangements and deletion of 6q22, containing the putative tumor suppressor gene PTPRK, are potential risk predictors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2006 Aug;65(8):776-82 [16896311.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):737-41 [12591717.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):447-51 [12640061.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):487-93 [12657933.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):164-9 [12802586.001]
  • [Cites] Cerebrovasc Dis. 2004;17(2-3):224-7 [14707426.001]
  • [Cites] Cell. 2004 Jun 11;117(6):699-711 [15186772.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Blood. 1994 Apr 1;83(7):1757-9 [8142643.001]
  • [Cites] Blood. 1994 May 1;83(9):2423-7 [8167331.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46 [17057753.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5711-5 [17116938.001]
  • [Cites] Blood. 1995 May 15;85(10):2877-84 [7742550.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):615-20 [9635710.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):123-33 [10337996.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1507-13 [15735126.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2233-9 [15800313.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3179-82 [16101124.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5718-27 [16009945.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2466-72 [16240449.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2332-43 [17625604.001]
  • [Cites] Blood. 2008 Jan 1;111(1):292-301 [17720884.001]
  • [Cites] Leukemia. 2008 Feb;22(2):400-5 [17989719.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1268-72 [17989713.001]
  • [Cites] Nat Rev Immunol. 2005 Jan;5(1):43-57 [15630428.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1445-51 [10550299.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1386-92 [10555007.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):261-6 [10659013.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):73-84 [10668897.001]
  • [Cites] Neurosurgery. 2000 Aug;47(2):454-6; discussion 456-7 [10942021.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Mar;125(2):147-50 [11369058.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Br J Haematol. 2002 May;117(2):322-32 [11972514.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Oct;61(10):926-33 [12387458.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1383-97 [8055462.001]
  • (PMID = 18645192.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA15083; United States / NCI NIH HHS / CA / P50 CA108961
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins
  • [Other-IDs] NLM/ PMC2653136
  •  go-up   go-down


55. Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E: Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood; 2008 Feb 1;111(3):1085-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report.
  • Isolated central nervous system (CNS) relapse involving the brain parenchyma is a rare complication of systemic non-Hodgkin lymphoma.
  • After complete response to initial non-Hodgkin lymphoma treatment, patients with isolated CNS relapse with the brain parenchyma as initial relapse site were eligible.
  • Patients with isolated CNS relapse involving only the cerebrospinal fluid were not eligible.
  • Brain relapse was identified by neuroimaging in all patients; in 54 (48%), diagnostic brain tumor specimen was obtained.
  • Our results suggest systemic methotrexate is the optimal treatment for isolated CNS relapse involving the brain parenchyma.
  • [MeSH-major] Brain Neoplasms / secondary. Central Nervous System Neoplasms / secondary. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cerebral Hemorrhage. Female. Humans. Male. Middle Aged. Recurrence


56. Mi S: Troy/Taj and its role in CNS axon regeneration. Cytokine Growth Factor Rev; 2008 Jun-Aug;19(3-4):245-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Troy/Taj and its role in CNS axon regeneration.
  • Troy/Taj is an orphan TNF family receptor that is broadly expressed in postnatal and adult neurons.
  • [MeSH-major] Central Nervous System / physiology. Nerve Regeneration. Receptors, Tumor Necrosis Factor / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18524667.001).
  • [ISSN] 1359-6101
  • [Journal-full-title] Cytokine & growth factor reviews
  • [ISO-abbreviation] Cytokine Growth Factor Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / LINGO1 protein, human; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / Receptor, Nerve Growth Factor; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF19 protein, human; 0 / Tnfrsf19 protein, mouse
  • [Number-of-references] 49
  •  go-up   go-down


57. Krasnianski M, Müller T, Stock K, Zierz S: Bruns syndrome caused by intraventricular tumor. Eur J Med Res; 2007 Dec 14;12(12):582-4
MedlinePlus Health Information. consumer health - Nausea and Vomiting.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bruns syndrome caused by intraventricular tumor.
  • Although the old neurological literature recognized tumors as well as neurocysticercosis as causes of the Bruns syndrome, during the last 60 years only intraventricular neurocysticercosis was reported to cause this symptom-complex.
  • The cranial MRI revealed a tumor in the third ventricle and a further tumor in the fourth ventricle, which could cause a transient obstruction of the CSF pathways.
  • This unusual observation of the Bruns syndrome in a non-parasitary disease of the CNS adds the syndrome to the differential diagnosis of paroxysmal vertigo.
  • [MeSH-major] Ataxia / diagnosis. Cerebral Ventricle Neoplasms / complications. Cerebral Ventricle Neoplasms / diagnosis. Headache / diagnosis. Vertigo / diagnosis. Vomiting / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Syndrome

  • MedlinePlus Health Information. consumer health - Dizziness and Vertigo.
  • MedlinePlus Health Information. consumer health - Headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024268.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Chojnacki A, Weiss S: Production of neurons, astrocytes and oligodendrocytes from mammalian CNS stem cells. Nat Protoc; 2008;3(6):935-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Production of neurons, astrocytes and oligodendrocytes from mammalian CNS stem cells.
  • The isolation and expansion of precursor cells in a serum-free culture system allows for the systematic characterization of their properties and the intrinsic and extrinsic signals that regulate their function.
  • The discovery of neural stem cells in the adult mouse brain was made possible by the creation of a novel culture system subsequently termed the neurosphere assay.
  • Therein, the dissociated adult mouse periventricular area was plated in the presence of epidermal growth factor, but in the absence of adhesive substrates, which resulted in the generation of spheres of proliferating cells that detached from the plate bottom and remained suspended in the media.
  • Since its inception, the neurosphere culture system has been widely used in the neural precursor cell field and has been extensively adapted for the isolation and expansion of corneal, cardiac, skin, prostate, mammary and brain tumor stem cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18536641.001).
  • [ISSN] 1750-2799
  • [Journal-full-title] Nature protocols
  • [ISO-abbreviation] Nat Protoc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


59. Cooper PB, Auerbach A, Aguilera NS, Adair C, Moores L, Geyer D, Rushing EJ: Rare primary CNS anaplastic large cell lymphoma in an immunocompetent adult: a clinical-pathologic case report and review case of the literature. Clin Neuropathol; 2006 Sep-Oct;25(5):232-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare primary CNS anaplastic large cell lymphoma in an immunocompetent adult: a clinical-pathologic case report and review case of the literature.
  • OBJECTIVE AND IMPORTANCE: Isolated anaplastic large cell lymphoma (ALCL) presenting in the primary central nervous system is distinctly uncommon.
  • The authors describe a case that clinically and radiographically simulated a primary glial neoplasm.
  • There appeared to be a clear demarcation between white matter and tumor with no obvious necrosis.
  • CONCLUSION: Reported in less than 20 patients, primary ALCL in an immunocompetent patient is rarely found intracranially; however, its ability to mimic glial neoplasms as well as other pathologies underlines its importance.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / analysis. Combined Modality Therapy. Diagnosis, Differential. Glioma / pathology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Radiotherapy. Seizures / etiology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Neuropathol. 2007 Jan-Feb;26(1):39-40; author reply 40 [17290938.001]
  • (PMID = 17007446.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


60. Erickson ML, Johnson R, Bannykh SI, de Lotbiniere A, Kim JH: Malignant rhabdoid tumor in a pregnant adult female: literature review of central nervous system rhabdoid tumors. J Neurooncol; 2005 Sep;74(3):311-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant rhabdoid tumor in a pregnant adult female: literature review of central nervous system rhabdoid tumors.
  • Rhabdoid tumors of the central nervous system are uncommon, aggressive childhood malignancies.
  • The 13 described adult cases comprise both primary CNS tumors and malignant transformation of previously existing gliomas, meningiomas, and astrocytomas.
  • Central nervous system rhabdoid lesions of adults have been diagnosed as primary malignant rhabdoid tumors, atypical teratoid/rhabdoid tumors, and more recently, rhabdoid glioblastomas.
  • Pathologic evaluation revealed histology, electron microscopy and immunohistochemistry consistent with the diagnosis of malignant rhabdoid tumor.
  • FISH studies were negative for the INI-1 genetic mutations and chromosome 22q deletion associated with childhood atypical rhabdoid/rhabdoid tumor in 75% of cases.
  • We briefly describe the characteristics and current understanding of rhabdoid tumors, and review the literature comparing the 12 other cases of central nervous system rhabdoid tumors in adults.
  • Furthermore, we consider and discuss the implications of this case being the second presentation of MRT during pregnancy in only six adult female patients.
  • [MeSH-major] Brain Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Microscopy, Electron, Transmission. Pregnancy

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2001 Mar;52(1):49-56 [11451202.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):121-6 [12622450.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):802-8 [11533659.001]
  • [Cites] Can J Neurol Sci. 1996 Nov;23(4):257-63 [8951203.001]
  • [Cites] Neuroradiology. 2000 May;42(5):363-7 [10872158.001]
  • [Cites] Obstet Gynecol. 1997 Jan;89(1):19-23 [8990430.001]
  • [Cites] Pathol Int. 1999 Dec;49(12):1114-8 [10632935.001]
  • [Cites] Genes Chromosomes Cancer. 2002 May;34(1):33-41 [11921280.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3461-7 [12429635.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] Oncogene. 2002 Sep 19;21(42):6403-12 [12226744.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):223-7 [9024522.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2759-63 [10914721.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Jun;29(3):254-61 [12787322.001]
  • [Cites] J Neuroimmunol. 2001 Nov 1;120(1-2):129-37 [11694327.001]
  • [Cites] Neurochirurgie. 1999 Sep;45(3):237-42 [10567965.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):81-5 [7679853.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Neuropathology. 2002 Dec;22(4):252-60 [12564764.001]
  • [Cites] Hum Pathol. 2001 Oct;32(10):1102-8 [11679945.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):289-305 [12482982.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):323-8 [11782395.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):156-62 [11230702.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):854-61 [11557780.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):7556-64 [9054461.001]
  • [Cites] J Clin Neurosci. 2003 May;10 (3):325-8 [12763338.001]
  • [Cites] Mod Pathol. 2002 Feb;15(2):146-53 [11850543.001]
  • [Cites] J Neurosurg. 2002 Dec;97(6):1450-5 [12507148.001]
  • [Cites] Int J Surg Pathol. 2001 Jan;9(1):37-48 [11469343.001]
  • [Cites] Med Phys. 1995 Jan;22(1):63-82 [7715571.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1482-90 [9850174.001]
  • [Cites] Clin Neuropathol. 2001 Nov-Dec;20(6):248-55 [11758780.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • [Cites] Mol Cell. 1999 Feb;3(2):247-53 [10078207.001]
  • [Cites] J Cell Physiol. 2003 Mar;194(3):303-13 [12548550.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):964-9 [11420471.001]
  • (PMID = 16132523.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Petit A, Sellers DL, Liebl DJ, Tessier-Lavigne M, Kennedy TE, Horner PJ: Adult spinal cord progenitor cells are repelled by netrin-1 in the embryonic and injured adult spinal cord. Proc Natl Acad Sci U S A; 2007 Nov 6;104(45):17837-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult spinal cord progenitor cells are repelled by netrin-1 in the embryonic and injured adult spinal cord.
  • Adult neural progenitor cells (aNPCs) exhibit limited migration in vivo with the exception of the rostral migratory stream and injury-induced movement.
  • These studies demonstrate that aNPCs respond principally to a repulsive cue expressed at the embryonic floor plate (FP) and also the injured adult CNS.
  • Adult spinal cord progenitor cells (aSCPs) were seeded onto organotypic slice preparations of the intact embryonic or injured adult spinal cord.
  • These studies establish Ntn-1 as a critical regulator of aSCP migration in the intact and injured CNS.

  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prog Brain Res. 2002;137:425-42 [12440385.001]
  • [Cites] J Neurosci Res. 2005 Apr 15;80(2):160-71 [15751027.001]
  • [Cites] Dev Dyn. 2003 Feb;226(2):245-56 [12557203.001]
  • [Cites] Cell. 2003 Apr 4;113(1):11-23 [12679031.001]
  • [Cites] Neuron. 2003 Sep 11;39(6):919-35 [12971893.001]
  • [Cites] Mol Cell Neurosci. 2003 Sep;24(1):171-89 [14550778.001]
  • [Cites] Trends Neurosci. 2003 Dec;26(12):641-3 [14624844.001]
  • [Cites] Nat Rev Neurosci. 2004 Feb;5(2):146-56 [14735117.001]
  • [Cites] J Neurosci. 2004 Feb 11;24(6):1497-506 [14960623.001]
  • [Cites] J Neurosci Res. 2004 Apr 15;76(2):223-31 [15048920.001]
  • [Cites] J Neurosci Res. 2004 Sep 1;77(5):690-700 [15352215.001]
  • [Cites] Development. 1987 Dec;101(4):685-96 [3503693.001]
  • [Cites] Nature. 1988 Dec 22-29;336(6201):775-8 [3205306.001]
  • [Cites] Trends Neurosci. 1988 May;11(5):227-31 [2471328.001]
  • [Cites] Cell. 1993 May 21;73(4):673-86 [8500163.001]
  • [Cites] Science. 1994 May 20;264(5162):1145-8 [8178174.001]
  • [Cites] Cell. 1994 Aug 12;78(3):409-24 [8062384.001]
  • [Cites] Cell. 1994 Aug 12;78(3):425-35 [8062385.001]
  • [Cites] J Cell Biol. 1995 Oct;131(2):453-64 [7593171.001]
  • [Cites] Science. 1996 Feb 16;271(5251):978-81 [8584933.001]
  • [Cites] Cell. 1996 Jul 12;86(1):35-46 [8689685.001]
  • [Cites] Neuron. 1996 Aug;17(2):203-15 [8780645.001]
  • [Cites] Science. 1996 Nov 15;274(5290):1123-33 [8895455.001]
  • [Cites] Cell. 1996 Nov 15;87(4):661-73 [8929535.001]
  • [Cites] Cell. 1996 Dec 13;87(6):1001-14 [8978605.001]
  • [Cites] Mol Cell Neurosci. 1997;8(6):417-29 [9143559.001]
  • [Cites] J Neurosci. 1997 Jul 1;17(13):5046-61 [9185542.001]
  • [Cites] Neurobiol Dis. 1995 Apr;2(2):79-85 [8980011.001]
  • [Cites] Neuron. 1997 Sep;19(3):575-89 [9331350.001]
  • [Cites] Development. 1998 Jun;125(12):2251-61 [9584124.001]
  • [Cites] Trends Neurosci. 2005 Nov;28(11):589-95 [16153715.001]
  • [Cites] Eur J Neurosci. 2005 Nov;22(9):2134-44 [16262652.001]
  • [Cites] Anat Rec B New Anat. 2005 Nov;287(1):4-13 [16308859.001]
  • [Cites] J Neurotrauma. 2006 Mar-Apr;23(3-4):409-21 [16629626.001]
  • [Cites] J Neurosci. 2006 Aug 23;26(34):8866-74 [16928876.001]
  • [Cites] J Comp Neurol. 2006 Oct 1;498(4):525-38 [16874803.001]
  • [Cites] Brain Res Rev. 2006 Sep;52(2):327-45 [16774788.001]
  • [Cites] J Neurosci Res. 2006 Dec;84(8):1808-20 [16998900.001]
  • [Cites] Arthritis Rheum. 2007 Jan;56(1):188-98 [17195221.001]
  • [Cites] Exp Neurol. 2000 Feb;161(2):563-70 [10686076.001]
  • [Cites] Mol Cell Neurosci. 2000 Oct;16(4):350-64 [11085873.001]
  • [Cites] J Neurosci. 2000 Dec 1;20(23):8727-35 [11102479.001]
  • [Cites] Exp Neurol. 2001 Mar;168(1):105-15 [11170725.001]
  • [Cites] J Neurosci. 2001 Jun 1;21(11):3911-22 [11356879.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):203-12 [11716071.001]
  • [Cites] Nat Neurosci. 2002 Oct;5(10):955-62 [12352982.001]
  • [Cites] Cell. 1998 May 15;93(4):581-91 [9604933.001]
  • [Cites] Development. 1998 Sep;125(18):3553-62 [9716521.001]
  • [Cites] Cell. 1999 Mar 19;96(6):795-806 [10102268.001]
  • [Cites] Cell. 1999 Jun 25;97(7):927-41 [10399920.001]
  • [Cites] Nature. 1999 Jul 22;400(6742):331-6 [10432110.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18117-22 [15608062.001]
  • [Cites] J Neurosci Res. 2003 Jan 1;71(1):7-22 [12478610.001]
  • (PMID = 17978191.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / R01 N546724
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Growth Factors; 0 / Tumor Suppressor Proteins; 147336-22-9 / Green Fluorescent Proteins; 158651-98-0 / netrin-1
  • [Other-IDs] NLM/ PMC2077035
  •  go-up   go-down


62. Galli R, Gritti A, Vescovi AL: Adult neural stem cells. Methods Mol Biol; 2008;438:67-84
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult neural stem cells.
  • Neural stem cells (NSCs) have been identified in the mature central nervous system (CNS), and they reside in specific areas.
  • The proper application of this method to the cells allows the establishment of long-term expanding stable NSC lines, starting from different neural tissues as the adult rodent CNS and human brain tumor specimens.
  • [MeSH-minor] Animals. Cell Differentiation. Cell Separation. Cells, Cultured. Central Nervous System / cytology. Central Nervous System / pathology. Dissection. Humans. Neoplastic Stem Cells / cytology. Rodentia

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18369750.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Goss B, Ford J: CNS germ cell tumors: pattern of failure and effects of radiation volume. J Med Assoc Thai; 2006 Apr;89(4):415-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS germ cell tumors: pattern of failure and effects of radiation volume.
  • This retrospective study was conducted to evaluate local control and overall survival after radiotherapy for patients with intracranial germ cell tumors and to investigate the influence of irradiated field on treatment outcome.
  • Thirty-two patients with surgically confirmed or suspected primary intracranial germ cell tumors (GCT) treated at the Division of Therapeutic Radiology and Oncology, Chiang Mai University, Chiang Mai, Thailand between January 1988 and December 1999 were reviewed Seven patients were not included in the analysis of treatment outcome and survival due to incompleteness of radiation treatment or death before the end of treatment.
  • Patients were irradiated to the primary tumor with an adequate margin in 7 patients, to the whole brain with a cone down boost in 8 patients.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Neoplasm Recurrence, Local. Neoplasms, Germ Cell and Embryonal / radiotherapy. Treatment Outcome
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Middle Aged. Pinealoma / mortality. Pinealoma / radiotherapy. Retrospective Studies. Risk Factors. Survival Rate. Thailand / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16696383.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


64. Krasnianski M, Müller T, Stock K, Zierz S: Bruns syndrome caused by intraventricular tumor. Eur J Med Res; 2008 Apr 30;13(4):179-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bruns syndrome caused by intraventricular tumor.
  • Although the old neurological literature recognized tumors as well as neurocysticercosis as causes of the Bruns syndrome, during the last 60 years only intraventricular neurocysticercosis was reported to cause this symptom-complex.
  • The cranial MRI revealed a tumor in the third ventricle and a further tumor in the fourth ventricle, which could cause a transient obstruction of the CSF pathways.
  • This unusual observation of the Bruns syndrome in a non-parasitary disease of the CNS adds the syndrome to the differential diagnosis of paroxysmal vertigo.
  • [MeSH-major] Ataxia / etiology. Cerebral Ventricle Neoplasms / complications. Cerebral Ventricle Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Fourth Ventricle / pathology. Head Movements. Headache / etiology. Humans. Magnetic Resonance Imaging. Syndrome. Vertigo / etiology. Vomiting / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18504174.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


65. Nishihara H, Ozaki Y, Ito T, Yoshinaga T, Tabu K, Tanino M, Nagashima K, Tanaka S: A case of cerebral ganglioneuronal tumor in the parietal lobe of an adult. Brain Tumor Pathol; 2008;25(1):45-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of cerebral ganglioneuronal tumor in the parietal lobe of an adult.
  • Central nervous system (CNS) neuroblastoma/ganglioneuroblastoma is one of the embryonal tumors with neuronal differentiation found in young adults, but it is most common in children, especially in those below the age of 5 years, whereas extraventricular neurocytoma, a rare neuroepithelial tumor with neuronal differentiation, mostly affects young adults.
  • Here we present a rare case of cerebral ganglioneuronal tumor that occurred in a 32-year-old woman.
  • The patient suffered from tonic convulsion, and computed tomography demonstrated a well-demarcated, round tumor 3.3 cm in size with marked calcification in the right parietal lobe.
  • Immunohistochemically, the tumor cells did not react with any neuronal molecules, except for chromogranin A in ganglion-like large tumor cells, but electron microscopy demonstrated the presence of synapse-like nerve terminal structures without mature postsynaptic density, suggesting the presence of neoplastic tumor components with neuronal differentiation; thus, this tumor was diagnosed as CNS ganglioneuroblastoma with possible low-grade malignancy because the Mib-1 labeling index was less than 3%-4%.
  • Here we discuss the histological entity of cerebral ganglioneuronal tumors, including extraventricular neurocytoma.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioneuroblastoma / pathology. Parietal Lobe / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18415666.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


66. Iosif RE, Ekdahl CT, Ahlenius H, Pronk CJ, Bonde S, Kokaia Z, Jacobsen SE, Lindvall O: Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci; 2006 Sep 20;26(38):9703-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis.
  • Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine, acting through the TNF-R1 and TNF-R2 receptors.
  • The two receptors have been proposed to mediate distinct TNF-alpha effects in the CNS, TNF-R1 contributing to neuronal damage and TNF-R2 being neuroprotective.
  • Whether TNF-alpha and its receptors play any role for neurogenesis in the adult brain is unclear.
  • Our data reveal differential actions of TNF-R1 and TNF-R2 signaling in adult hippocampal neurogenesis and identify for the first time TNF-R1 as a negative regulator of neural progenitor proliferation in both the intact and pathological brain.
  • [MeSH-major] Cell Proliferation. Growth Inhibitors / physiology. Hippocampus / cytology. Hippocampus / physiology. Neurons / cytology. Receptors, Tumor Necrosis Factor, Type I / physiology. Stem Cells / cytology. Stem Cells / physiology
  • [MeSH-minor] Animals. Cells, Cultured. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Receptors, Tumor Necrosis Factor, Type II / deficiency. Receptors, Tumor Necrosis Factor, Type II / physiology


67. Yang SH, Lee KS, Kim IS, Hong JT, Sung JH, Son BC, Lee SW, Hong YK: Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant. J Neurooncol; 2009 Mar;92(1):65-71
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant.
  • We report a single-center experience of 16 immunocompetent patients diagnosed with primary central nervous system lymphoma and treated with monochemotherapy with high-dose methotrexate (MTX) and deferred radiotherapy.
  • There were eight complete responses (CR), one partial response, one stable disease, and six patients whose tumors progressed in spite of the chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Central Nervous System Neoplasms / metabolism. Lymphoma, Non-Hodgkin / metabolism. Methotrexate / administration & dosage. STAT6 Transcription Factor / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Differentiation. 2002 Dec;70(9-10):537-46 [12492495.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):556-64 [8636771.001]
  • [Cites] Neurosurgery. 2000 Jan;46(1):51-60; discussion 60-1 [10626935.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):94-103 [6689733.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):939-47 [2914300.001]
  • [Cites] Cell Res. 2007 Nov;17(11):942-55 [17968425.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Ann Neurol. 2005 Jun;57(6):843-7 [15929034.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Mar;57(3):245-53 [16213149.001]
  • [Cites] Blood. 2002 Jan 15;99(2):618-26 [11781246.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Neurosci. 1998 Oct;5(4):409-12 [18639063.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2924-32 [15591113.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):519-26 [10653867.001]
  • [Cites] Neurology. 1996 Jun;46(6):1757-9 [8649588.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1580-90 [1875220.001]
  • [Cites] Neurology. 1996 Feb;46(2):435-9 [8614508.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):259-68 [10563432.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(11):1682-8 [15251157.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1550-64 [17705178.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Neurology. 2004 Feb 24;62(4):544-7 [14981168.001]
  • [Cites] Neuro Oncol. 2000 Jan;2(1):40-4 [11302253.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):457-64 [11380234.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jun;130(6):351-6 [15034788.001]
  • [Cites] Radiology. 1990 Sep;176(3):855-60 [2389047.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Onkologie. 2006 Oct;29(10):455-9 [17028454.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6333-41 [16144938.001]
  • (PMID = 19030780.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / STAT6 Transcription Factor; 0 / STAT6 protein, human; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


68. Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME: Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol; 2007 Feb 1;25(4):399-404
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
  • PURPOSE: This phase I trial was designed to (1) establish the dose of O6-benzylguanine (O6-BG) administered intravenously as a continuous infusion that suppresses O6-alkylguanine-DNA alkyltransferase (AGT) levels in brain tumors, (2) evaluate the safety of extending continuous-infusion O6-BG at the optimal dose with intracranially implanted carmustine wafers, and (3) measure the pharmacokinetics of O6-BG and its metabolite.
  • Tumor samples were evaluated for AGT levels.
  • Future trials are required to determine if the inhibition of tumor AGT levels results in increased efficacy.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3025-31 [10955780.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3570-5 [9817277.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7178-87 [16192602.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6307-10 [11103789.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):28-32 [14769137.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Commun. 1990;2(11):371-7 [2242301.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):441-6 [1993909.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3367-72 [1647266.001]
  • [Cites] J Neurosurg. 1992 Apr;76(4):640-7 [1545259.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(6):471-6 [8258196.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5123-30 [7923129.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1030-6 [8855970.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1803-10 [9586894.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3522-8 [11032594.001]
  • (PMID = 17264335.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA14599; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCRR NIH HHS / RR / M01 RR000055; United States / NCI NIH HHS / CA / U01 CA069852-12; United States / NCRR NIH HHS / RR / M01 RR000055-400764; United States / NCI NIH HHS / CA / CA69852; United States / NCRR NIH HHS / RR / RR000055-400764; United States / NCI NIH HHS / CA / CA069852-12; United States / NCI NIH HHS / CA / P30 CA014599-289015; United States / NCI NIH HHS / CA / CA62475; United States / NCI NIH HHS / CA / U01 CA069852; United States / NCI NIH HHS / CA / CA014599-289015
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / carmustine with prolifeprosan 20; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ NIHMS66419; NLM/ PMC2556256
  •  go-up   go-down


69. Hisaoka T, Morikawa Y, Senba E: Characterization of TROY/TNFRSF19/TAJ-expressing cells in the adult mouse forebrain. Brain Res; 2006 Sep 19;1110(1):81-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of TROY/TNFRSF19/TAJ-expressing cells in the adult mouse forebrain.
  • A member of the tumor necrosis factor receptor superfamily (TNFRSF), TROY/TNFRSF19/TAJ, is highly expressed in the brain of adult mice.
  • Northern blot analysis using mRNA taken from regions of the adult CNS showed the expression of TROY in all regions examined, including the olfactory bulb, cerebral cortex, striatum, and hippocampus.
  • In situ hybridization and immunohistochemistry revealed that TROY mRNA and protein were strongly expressed in the rostral migratory stream (RMS) and subventricular zone (SVZ) of adult mice.
  • In the adult SVZ, some glial fibrillary acidic protein (GFAP)-positive cells (type B cells) are thought to be multipotent neural stem cells.
  • TROY-expressing cells were GFAP-positive, EGFR-positive, and TuJ1-negative in the adult SVZ.
  • Thus, TROY was expressed in uncommitted precursor cells and astroglial lineage cells, suggesting that TROY plays some roles in the regulation of gliogenesis in the adult CNS.
  • [MeSH-major] Gene Expression / physiology. Neuroglia / metabolism. Neurons / metabolism. Prosencephalon / cytology. Receptors, Tumor Necrosis Factor / metabolism

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16870160.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Receptors, Tumor Necrosis Factor; 0 / Tnfrsf19 protein, mouse; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


70. MacFadyen J, Savage K, Wienke D, Isacke CM: Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development. Gene Expr Patterns; 2007 Jan;7(3):363-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development.
  • Finally, the fibroblast and pericyte expression of endosialin changes dynamically during development and becomes highly restricted in adult mouse tissues.
  • [MeSH-major] Antigens, CD / genetics. Central Nervous System / blood supply. Down-Regulation. Fibroblasts / metabolism. Gene Expression Regulation, Developmental. Neoplasm Proteins / genetics. Pericytes / metabolism


71. Ogino H, Shibamoto Y, Takanaka T, Suzuki K, Ishihara S, Yamada T, Sugie C, Nomoto Y, Mimura M: CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):803-8
Genetic Alliance. consumer health - Germinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome.
  • PURPOSE: The prognostic significance of human chorionic gonadotropin (HCG) level in central nervous system germinoma remains controversial.
  • METHODS AND MATERIALS: We undertook a multi-institutional retrospective analysis of 103 patients with central nervous system germinoma whose serum HCG and/or beta-HCG level had been measured before treatment between 1984 and 2002.
  • The proportion of HCG-producing tumors was higher in the lesions at the basal ganglia than in the lesions at the other sites.
  • No correlation was found between tumor size and HCG level, but there seemed to be a weak correlation between size and beta-HCG.
  • Also, no other patient-, tumor-, or treatment-related factors seemed to influence the prognosis of the patients.
  • Relationship between tumor size and site and HCG level should be investigated further.
  • [MeSH-major] Central Nervous System Neoplasms / blood. Chorionic Gonadotropin / blood. Germinoma / blood. Neoplasm Proteins / blood
  • [MeSH-minor] Adolescent. Adult. Chorionic Gonadotropin, beta Subunit, Human / blood. Female. Humans. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936563.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Neoplasm Proteins
  •  go-up   go-down


72. Wolf RL, Wang J, Wang S, Melhem ER, O'Rourke DM, Judy KD, Detre JA: Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J Magn Reson Imaging; 2005 Oct;22(4):475-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla.
  • MATERIALS AND METHODS: CASL perfusion images were obtained preoperatively in 26 patients with brain neoplasms (19 high-grade gliomas (HGGs; WHO grades 3 and 4) and seven low-grade gliomas (LGGs; WHO grades 1 and 2)).
  • The mean and maximum tumor blood flow (TBF and TBFmax) were calculated in the neoplasm, including surrounding infiltrating tumor vs. edema.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Angiography / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Spin Labels

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16161080.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K23 NS43381; United States / NINDS NIH HHS / NS / NS045839; United States / NCRR NIH HHS / RR / RR002305
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Spin Labels
  •  go-up   go-down


73. Floden AM, Combs CK: Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. J Neurosci; 2006 Apr 26;26(17):4644-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner.
  • To determine whether Abeta stimulatory phenotypes differ between young and adult microglia, we established cultures of acutely isolated adult murine cortical microglia to compare with postnatal derived microglial cultures.
  • Fibrillar Abeta was rapidly phagocytosed by postnatal microglia and both oligomeric and fibrillar peptide stimulated increased tumor necrosis factor alpha (TNFalpha) secretion.
  • However, Abeta oligomers but not fibrils stimulated TNFalpha secretion from adult microglia.
  • More importantly, adult microglia had diminished ability to phagocytose Abeta fibrils.
  • These findings demonstrate that adult microglia respond to Abeta fibril stimulation uniquely from postnatal cells and suggest that adult rather than postnatal microglia cultures are more appropriate for modeling proinflammatory changes in the aged CNS.
  • [MeSH-major] Aging / immunology. Amyloid beta-Peptides / administration & dosage. Brain / immunology. Microglia / immunology. Peptide Fragments / administration & dosage. Phagocytosis / immunology. Tumor Necrosis Factor-alpha / immunology

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16641245.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 P20 RR17699-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid beta-Peptides; 0 / Peptide Fragments; 0 / Tumor Necrosis Factor-alpha; 0 / amyloid beta-protein (1-42)
  •  go-up   go-down


74. Zhang D, Hu LB, Henning TD, Ravarani EM, Zou LG, Feng XY, Wang WX, Wen L: MRI findings of primary CNS lymphoma in 26 immunocompetent patients. Korean J Radiol; 2010 May-Jun;11(3):269-77
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI findings of primary CNS lymphoma in 26 immunocompetent patients.
  • OBJECTIVE: To record the MR imaging features of primary central nervous system lymphoma (PCNSL) and compare these features in monofocal and multifocal disease.
  • Tumor location, tumor size, signal intensity, enhancement characteristics, age distribution, peritumoral edema, cystic changes, and the presence of calcifications were assessed.
  • Tumor size differed significantly between the two groups (t = 3.129, p < 0.01) and mildly or moderately enhanced lesions were more frequently found in the monofocal group (p < 0.05).
  • Monofocal PCNSL cases typically have larger sized tumors with mild or moderate enhancement.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Immunocompetence. Lymphoma / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Contrast Media. Female. Gadolinium DTPA. Humans. Image Enhancement / methods. Male. Middle Aged. Observer Variation. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 1999;16(1):29-35 [10532421.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):199-201 [10563423.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):219-26 [10563426.001]
  • [Cites] Neuroradiology. 1999 Nov;41(11):820-5 [10602854.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1427-33 [10751251.001]
  • [Cites] Neuroradiology. 2000 Oct;42(10):738-41 [11110076.001]
  • [Cites] AJR Am J Roentgenol. 2001 May;176(5):1319-26 [11312202.001]
  • [Cites] Eur Radiol. 2002 Feb;12(2):329-40 [11870430.001]
  • [Cites] Clin Neurol Neurosurg. 2003 Apr;105(2):78-86 [12691795.001]
  • [Cites] Clin Radiol. 1982 May 3;33(3):331-6 [7075140.001]
  • [Cites] Neuroradiology. 1984;26(6):485-92 [6504318.001]
  • [Cites] AJR Am J Roentgenol. 1986 Feb;146(2):271-6 [3484575.001]
  • [Cites] J Neurosurg. 1986 Nov;65(5):592-9 [3772444.001]
  • [Cites] Radiology. 1988 Apr;167(1):211-5 [3279454.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):835-53 [3286832.001]
  • [Cites] Neuroradiology. 1992;34(1):36-42 [1553036.001]
  • [Cites] Ann Neurol. 1993 Mar;33(3):308-11 [8498814.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1383-97 [8055462.001]
  • [Cites] Clin Radiol. 1994 Oct;49(10):696-702 [7955832.001]
  • [Cites] Radiology. 1995 Jan;194(1):271-6 [7997566.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):77-82 [7815138.001]
  • [Cites] AJR Am J Roentgenol. 1995 Sep;165(3):626 [7645482.001]
  • [Cites] Neuroradiology. 1996 Jan;38(1):34-7 [8773272.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Mar;18(3):563-72 [9090424.001]
  • [Cites] Ann Oncol. 1997 Mar;8(3):227-34 [9137790.001]
  • [Cites] Radiographics. 1997 Nov-Dec;17(6):1497-526 [9397461.001]
  • [Cites] Clin Radiol. 1998 Jun;53(6):428-34 [9651058.001]
  • [Cites] Neurochirurgie. 1997;43(6):385-7 [9706618.001]
  • [Cites] Clin Neurol Neurosurg. 2004 Dec;107(1):55-63 [15567554.001]
  • [Cites] AJR Am J Roentgenol. 2005 May;184(5):1679-85 [15855138.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):169-77 [15925998.001]
  • [CommentIn] Korean J Radiol. 2010 Nov-Dec;11(6):702-3 [21076600.001]
  • (PMID = 20461180.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ PMC2864853
  • [Keywords] NOTNLM ; Brain neoplasm / Computed tomography (CT) / Lymphoma / Magnetic resonance (MR)
  •  go-up   go-down


75. Jayadev S, Yun B, Nguyen H, Yokoo H, Morrison RS, Garden GA: The glial response to CNS HIV infection includes p53 activation and increased expression of p53 target genes. J Neuroimmune Pharmacol; 2007 Dec;2(4):359-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The glial response to CNS HIV infection includes p53 activation and increased expression of p53 target genes.
  • We have also shown that microglia from p53-deficient mice fail to induce neurotoxicity in response to the HIV coat protein gp120 in a coculture system, supporting the hypothesis that p53 plays a pathogenic role in the chronic neuroinflammatory component of HIV-associated neurodegeneration.
  • [MeSH-major] AIDS Dementia Complex / genetics. AIDS Dementia Complex / metabolism. Central Nervous System Infections / metabolism. Gene Expression Regulation, Viral / physiology. Neuroglia / metabolism. Neuroglia / virology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Astrocytes / metabolism. Astrocytes / pathology. Astrocytes / virology. Female. Gene Targeting. HeLa Cells. Humans. Male. Microglia / metabolism. Microglia / pathology. Microglia / virology. Middle Aged. Oligodendroglia / metabolism. Oligodendroglia / pathology. Oligodendroglia / virology. Signal Transduction / genetics. Signal Transduction / physiology

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroscience. 2001;103(1):203-18 [11311801.001]
  • [Cites] Am J Pathol. 1996 Sep;149(3):1027-53 [8780406.001]
  • [Cites] Neuron. 1996 Mar;16(3):675-86 [8785064.001]
  • [Cites] Cancer Lett. 2004 Jan 20;203(2):199-207 [14732228.001]
  • [Cites] N Engl J Med. 1995 Apr 6;332(14):934-40 [7877652.001]
  • [Cites] J Neurosci Res. 1997 Dec 1;50(5):798-808 [9418967.001]
  • [Cites] Neurology. 2003 Jan 28;60(2):307-14 [12552050.001]
  • [Cites] Dev Biol. 2006 May 15;293(2):358-69 [16581057.001]
  • [Cites] Brain Pathol. 1999 Apr;9(2):209-17 [10219738.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):851-8 [15865941.001]
  • [Cites] FASEB J. 2004 Jul;18(10):1141-3 [15155568.001]
  • [Cites] AIDS. 2000 Sep 8;14(13):1949-54 [10997399.001]
  • [Cites] Neurology. 1993 Nov;43(11):2230-7 [8232935.001]
  • [Cites] J Leukoc Biol. 1994 Sep;56(3):389-98 [8083614.001]
  • [Cites] Ann Neurol. 2001 Jun;49(6):745-52 [11409426.001]
  • [Cites] Am J Pathol. 2005 Sep;167(3):695-704 [16127150.001]
  • [Cites] Curr Opin Neurol. 2001 Jun;14(3):375-9 [11371763.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Jul 23;71(1):78-86 [10407189.001]
  • [Cites] J Alzheimers Dis. 2001 Feb;3(1):31-40 [12214070.001]
  • [Cites] Adv Neuroimmunol. 1995;5(3):335-58 [8748077.001]
  • [Cites] Semin Neurol. 1999;19(2):113-27 [10718533.001]
  • [Cites] Science. 1990 Dec 14;250(4987):1593-6 [2148832.001]
  • [Cites] Exp Neurol. 2006 Oct;201(2):349-58 [16814281.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):988-92 [16372019.001]
  • [Cites] Glia. 1993 Jan;7(1):102-10 [8423057.001]
  • [Cites] Nature. 2001 Apr 19;410(6831):988-94 [11309629.001]
  • [Cites] J Cell Physiol. 2002 Jul;192(1):1-15 [12115731.001]
  • [Cites] Cell Death Differ. 2005 Aug;12 Suppl 1:855-8 [15846379.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):16202-12 [10821866.001]
  • [Cites] J Cell Physiol. 1999 Nov;181(2):231-9 [10497302.001]
  • [Cites] Neurobiol Aging. 2005 Mar;26(3):349-54 [15639313.001]
  • [Cites] J Neurosci. 2003 Sep 24;23(25):8682-91 [14507967.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12 ):6763-8 [10823891.001]
  • [Cites] J Neural Transm Suppl. 1999;57:87-97 [10666670.001]
  • [Cites] J Neurotrauma. 2004 Jun;21(6):754-74 [15253803.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Feb 14;182(3):1201-7 [1540165.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1121-30 [7747806.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 1;11(1):39-44 [8528731.001]
  • [Cites] Nature. 1997 May 15;387(6630):299-303 [9153396.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2001 Aug;251(4):159-69 [11697580.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2769-73 [8464887.001]
  • [Cites] Neurochem Res. 2003 Jan;28(1):15-27 [12587660.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1010-4 [14963330.001]
  • [Cites] Brain Pathol. 1991 Apr;1(3):143-52 [1669703.001]
  • [Cites] J Neurosci. 1995 Nov;15(11):7712-26 [7472522.001]
  • [Cites] Neuropathol Appl Neurobiol. 1999 Apr;25(2):123-33 [10216000.001]
  • [Cites] Toxicol Lett. 2003 Apr 4;139(2-3):199-206 [12628755.001]
  • [Cites] Nature. 1997 May 15;387(6630):296-9 [9153395.001]
  • [Cites] Arch Neurol. 2002 Dec;59(12):1930-6 [12470182.001]
  • [Cites] Lab Invest. 1998 Apr;78(4):401-11 [9564885.001]
  • [Cites] Development. 2004 Mar;131(6):1211-20 [14960496.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 17;232(2):418-21 [9125193.001]
  • [Cites] Ann Neurol. 1992 Sep;32(3):321-9 [1416802.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):195-210 [12744473.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1717-25 [15111318.001]
  • [Cites] Ann Neurol. 1993 Jul;34(1):65-70 [8517682.001]
  • [Cites] Science. 1996 Jul 5;273(5271):59-63 [8658196.001]
  • [Cites] Nat Neurosci. 2001 Jul;4(7):702-10 [11426226.001]
  • [Cites] Ann Neurol. 1995 Nov;38(5):755-62 [7486867.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1115-20 [11048806.001]
  • [Cites] Ann Neurol. 1991 Jun;29(6):651-7 [1909852.001]
  • [Cites] Cell Mol Life Sci. 2004 Apr;61(7-8):822-42 [15095006.001]
  • [Cites] J Neurovirol. 2000 May;6 Suppl 1:S38-43 [10871764.001]
  • [Cites] Oncogene. 1999 Nov 1;18(45):6145-57 [10557106.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8212-6 [10393974.001]
  • [Cites] Science. 2006 Jun 16;312(5780):1650-3 [16728594.001]
  • [Cites] Science. 2000 Apr 21;288(5465):440-2 [10798979.001]
  • [Cites] Neurobiol Dis. 2000 Dec;7(6 Pt B):613-22 [11114260.001]
  • [Cites] J Neurovirol. 2004;10 Suppl 1:97-101 [14982746.001]
  • [Cites] Prog Neurobiol. 2004 Feb;72(2):111-27 [15063528.001]
  • [Cites] Glia. 2002 Nov;40(2):240-51 [12379911.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Oncogene. 2001 Mar 8;20(10):1212-9 [11313865.001]
  • [Cites] Ann Neurol. 1997 Dec;42(6):963-72 [9403489.001]
  • [Cites] Neurology. 1992 Aug;42(8):1472-6 [1641138.001]
  • [Cites] Ann Neurol. 2003 Nov;54(5):605-14 [14595650.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):1979-90 [8903316.001]
  • (PMID = 18040854.001).
  • [ISSN] 1557-1904
  • [Journal-full-title] Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
  • [ISO-abbreviation] J Neuroimmune Pharmacol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS35533; United States / NICHD NIH HHS / HD / P30-HD02774; United States / NIA NIH HHS / AG / T32-AG000268; United States / NINDS NIH HHS / NS / NS45528; United States / NIMH NIH HHS / MH / U01 MH083545; United States / NIMH NIH HHS / MH / N01MH32002
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


76. Chuang SS, Huang WT, Hsieh PP, Jung YC, Ye H, Du MQ, Lu CL, Cho CY, Hsiao SC, Hsu YH, Lin KJ: Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features. Histopathology; 2008 Mar;52(4):427-35
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features.
  • METHODS AND RESULTS: A retrospective study of 17 paediatric and 14 adult BLs with history and histopathology review, immunohistochemistry, Epstein-Barr virus (EBV) in situ hybridization (EBER) and fluorescence in situ hybridization.
  • There was no statistically significant difference in gender, frequency of central nervous system (CNS) involvement and leukaemic change at presentation, or frequency of CD10+/Bcl-2-/Bcl-6+ (88% versus 86%), Ki67 labelling index, EBER (24% versus 21%), or C-MYC translocation (100% versus 92%) between paediatric and adult tumours.
  • Correct pretreatment diagnoses were made in 13/17 (76%) paediatric and in 9/14 (64%) adult tumours.
  • Twenty-eight patients received chemotherapy including 13/16 (81%) paediatric and 3/12 (25%) adult patients with appropriate regimens; 16 (57%) received CNS prophylaxis.
  • CONCLUSIONS: Sporadic paediatric and adult BLs were phenotypically and genotypically similar.
  • The significant prognosticators were age (P = 0.001), with or without CNS prophylaxis (P = 0.004), and CNS involvement (P = 0.008) and leukaemic change (P = 0.019) in disease course.
  • The poor outcome in adult patients might be related to incorrect diagnosis and inappropriate treatment.
  • [MeSH-major] Burkitt Lymphoma / pathology. Central Nervous System Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Child, Preschool. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / virology. Female. Genotype. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization, Fluorescence. Infant. Male. Middle Aged. Phenotype. RNA, Viral / analysis. RNA-Binding Proteins / analysis. Retrospective Studies. Ribosomal Proteins / analysis. Survival Rate. Taiwan / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315595.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Viral; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


77. Pels H, Juergens A, Schirgens I, Glasmacher A, Schulz H, Engert A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Deckert M, Fimmers R, Urbach H, Schmidt-Wolf IG, Schlegel U: Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. Neuro Oncol; 2010 Jul;12(7):720-4
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma.
  • In primary central nervous system lymphoma (PCNSL), 2 international prognostic scores have been developed to estimate the outcome according to certain "prognostic groups".
  • In this analysis, we addressed the question of whether early tumor remission in patients still under therapy, according to magnetic resonance imaging (MRI) criteria, helps to predict long-term outcome.
  • Early complete tumor response assessed by MRI after the second of sixth scheduled chemotherapy cycles was highly predictive for both OS and TTF in patients with PCNSL treated in this series.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / drug therapy. Lymphoma / diagnosis. Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pilot Projects. Predictive Value of Tests. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Curr Neurol Neurosci Rep. 2002 May;2(3):210-5 [11936999.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Breast Cancer Res Treat. 2003 Mar;78(1):51-8 [12611457.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4483-8 [14597741.001]
  • [Cites] Clin Radiol. 1995 Jun;50(6):384-90 [7789022.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):615-20 [9635710.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):346-56 [10375091.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4489-95 [14597744.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1514-23 [15980161.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3865-70 [16864853.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5711-5 [17116938.001]
  • [Cites] Top Magn Reson Imaging. 2006 Apr;17(2):63-8 [17198223.001]
  • [Cites] Cancer Imaging. 2007;7:10-8 [17766210.001]
  • [Cites] J Magn Reson Imaging. 2007 Sep;26(3):615-23 [17729334.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4730-5 [17947720.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2512-8 [18413641.001]
  • (PMID = 20159882.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2940662
  •  go-up   go-down


78. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, Spivey JR, Saito K, Miller AH: CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry; 2010 Apr;15(4):393-403
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.
  • However, whether peripheral blood changes in these IDO catabolites are manifest in the brain and whether they are related to central nervous system cytokine responses and/or behavior is unknown.
  • Increases in CSF KYN and QUIN were correlated with increased CSF IFN-alpha, soluble tumor necrosis factor-alpha receptor 2 and monocyte chemoattractant protein-1 as well as increased depressive symptoms.
  • In conclusion, peripheral administration of IFN-alpha activated IDO in concert with central cytokine responses, resulting in increased brain KYN and QUIN, which correlated with depressive symptoms.

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • Hazardous Substances Data Bank. QUINOLINIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Glia. 2003 Mar;41(4):371-81 [12555204.001]
  • [Cites] Am J Psychiatry. 2003 Jul;160(7):1342-5 [12832253.001]
  • [Cites] J Interferon Cytokine Res. 2003 Aug;23(8):413-21 [13678429.001]
  • [Cites] Biol Psychiatry. 2003 Nov 1;54(9):906-14 [14573318.001]
  • [Cites] Adv Exp Med Biol. 2003;527:27-35 [15206713.001]
  • [Cites] Adv Exp Med Biol. 2003;527:105-12 [15206722.001]
  • [Cites] Adv Exp Med Biol. 2003;527:137-45 [15206726.001]
  • [Cites] J Neurochem. 2004 Oct;91(1):220-9 [15379902.001]
  • [Cites] Psychopharmacology (Berl). 1978 Dec 8;59(3):263-6 [104330.001]
  • [Cites] Br J Psychiatry. 1979 Apr;134:382-9 [444788.001]
  • [Cites] Psychopharmacology (Berl). 1982;76(1):79-83 [6805013.001]
  • [Cites] Arch Gen Psychiatry. 1983 Jul;40(7):812 [6860082.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3(9):873-6 [2166783.001]
  • [Cites] Pharmacol Biochem Behav. 1990 Sep;37(1):71-6 [2263669.001]
  • [Cites] J Neurochem. 1991 Jun;56(6):2007-17 [1827495.001]
  • [Cites] Neurochem Res. 1991 Oct;16(10):1139-43 [1686636.001]
  • [Cites] Brain. 1992 Oct;115 ( Pt 5):1249-73 [1422788.001]
  • [Cites] J Biol Chem. 1993 Jul 25;268(21):15496-503 [8340378.001]
  • [Cites] Brain. 1993 Dec;116 ( Pt 6):1425-50 [8293279.001]
  • [Cites] Clin Chem. 1994 Feb;40(2):288-95 [7508830.001]
  • [Cites] Biol Psychiatry. 1994 Jul 15;36(2):97-102 [7948450.001]
  • [Cites] Brain Res. 1996 Mar 4;711(1-2):163-74 [8680860.001]
  • [Cites] Brain Res. 1997 Feb 7;747(2):348-51 [9046014.001]
  • [Cites] Neuroimmunomodulation. 1996 Nov-Dec;3(6):352-7 [9266546.001]
  • [Cites] J Interferon Cytokine Res. 1997 Oct;17(10):589-95 [9355959.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6896-903 [9862722.001]
  • [Cites] Glia. 2005 Jan 1;49(1):15-23 [15390107.001]
  • [Cites] Biol Psychiatry. 2004 Dec 1;56(11):819-24 [15576057.001]
  • [Cites] J Clin Psychiatry. 2005 Jan;66(1):41-8 [15669887.001]
  • [Cites] Mol Psychiatry. 2005 Jun;10(6):538-44 [15494706.001]
  • [Cites] J Affect Disord. 2005 Jun;86(2-3):135-42 [15935232.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Aug;31(4):395-404 [16008823.001]
  • [Cites] Lancet. 2006 Jan 7;367(9504):29-35 [16399150.001]
  • [Cites] J Biochem. 2006 Apr;139(4):655-62 [16672265.001]
  • [Cites] Mol Psychiatry. 2006 Jul;11(7):680-4 [16491133.001]
  • [Cites] Neurodegener Dis. 2005;2(3-4):166-76 [16909022.001]
  • [Cites] Cytokine. 2006 Jul;35(1-2):53-61 [16931033.001]
  • [Cites] J Neural Transm (Vienna). 2007 Jan;114(1):33-41 [16932989.001]
  • [Cites] J Affect Disord. 2007 Feb;98(1-2):143-51 [16952400.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Jul;133(7):477-85 [17356858.001]
  • [Cites] Brain Behav Immun. 2007 Aug;21(6):727-35 [17604598.001]
  • [Cites] Mol Psychiatry. 2007 Nov;12(11):988-1000 [17457312.001]
  • [Cites] Biol Psychiatry. 2007 Dec 1;62(11):1324-33 [17678633.001]
  • [Cites] Nat Rev Neurosci. 2008 Jan;9(1):46-56 [18073775.001]
  • [Cites] Prog Neurobiol. 2008 May;85(1):1-74 [18346832.001]
  • [Cites] J Neurochem. 2008 May;105(4):1346-57 [18221377.001]
  • [Cites] Biol Psychiatry. 2008 Jun 1;63(11):1022-9 [18242584.001]
  • [Cites] CNS Spectr. 2008 Jun;13(6):501-10 [18567974.001]
  • [Cites] Brain Behav Immun. 2008 Aug;22(6):870-80 [18258414.001]
  • [Cites] Psychosom Med. 2009 Jan;71(1):57-62 [19073750.001]
  • [Cites] Biol Psychiatry. 2009 Feb 15;65(4):296-303 [18801471.001]
  • [Cites] J Neurosci. 2009 Feb 18;29(7):2089-102 [19228962.001]
  • [Cites] J Immunol. 2009 Mar 1;182(5):3202-12 [19234218.001]
  • [Cites] Biol Psychiatry. 2009 May 1;65(9):732-41 [19150053.001]
  • [Cites] Mol Psychiatry. 2009 May;14(5):511-22 [18195714.001]
  • [Cites] J Affect Disord. 2009 Dec;119(1-3):181-5 [19269036.001]
  • [Cites] Mol Psychiatry. 2010 May;15(5):535-47 [18521089.001]
  • [Cites] Arch Gen Psychiatry. 2001 May;58(5):445-52 [11343523.001]
  • [Cites] Mol Psychiatry. 2001 Jul;6(4):475-80 [11443537.001]
  • [Cites] Brain Behav Immun. 2001 Sep;15(3):199-226 [11566046.001]
  • [Cites] J Clin Psychopharmacol. 2002 Feb;22(1):86-90 [11799348.001]
  • [Cites] Neuropsychopharmacology. 2002 May;26(5):643-52 [11927189.001]
  • [Cites] Mol Psychiatry. 2002;7(5):468-73 [12082564.001]
  • [Cites] Life Sci. 2002 Sep 6;71(16):1837-48 [12175700.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Oct;303(1):1-10 [12235226.001]
  • [Cites] Brain Behav Immun. 2002 Oct;16(5):590-5 [12401473.001]
  • (PMID = 19918244.001).
  • [ISSN] 1476-5578
  • [Journal-full-title] Molecular psychiatry
  • [ISO-abbreviation] Mol. Psychiatry
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR0039; United States / NIMH NIH HHS / MH / K23 MH064619; United States / NIMH NIH HHS / MH / R01 MH 079829; United States / NHLBI NIH HHS / HL / R01 HL073921-05; United States / NIMH NIH HHS / MH / R01 MH083746; United States / NIA NIH HHS / AG / R01 AG029573; United States / NIMH NIH HHS / MH / R01 MH070553; United States / NIMH NIH HHS / MH / K23 MH064619-05; United States / NCRR NIH HHS / RR / M01 RR000039; United States / NHLBI NIH HHS / HL / R01 HL073921; United States / NIMH NIH HHS / MH / T32 MH020018; United States / NIMH NIH HHS / MH / K05 MH069124; United States / NIA NIH HHS / AG / R01 AG 029573; United States / NIMH NIH HHS / MH / R01 MH070553-05; United States / NIMH NIH HHS / MH / MH064619-05; United States / NIMH NIH HHS / MH / R01 MH071349; United States / NCATS NIH HHS / TR / UL1 TR000454; United States / NIMH NIH HHS / MH / MH069124-05; United States / NHLBI NIH HHS / HL / HL073921-05; United States / NIMH NIH HHS / MH / R01 MH 71349; United States / NIMH NIH HHS / MH / K05 MH069124-05; United States / NCRR NIH HHS / RR / UL1 RR025008; United States / NIMH NIH HHS / MH / R01 MH079829; United States / NIMH NIH HHS / MH / MH070553-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Chemokine CCL2; 0 / Cytokines; 0 / Interferon-alpha; 0 / Receptors, Tumor Necrosis Factor, Type II; 343-65-7 / Kynurenine; 49717AWG6K / Ribavirin; 8DUH1N11BX / Tryptophan; F6F0HK1URN / Quinolinic Acid
  • [Other-IDs] NLM/ NIHMS147985; NLM/ PMC2844942
  •  go-up   go-down


79. Cassiani-Ingoni R, Coksaygan T, Xue H, Reichert-Scrivner SA, Wiendl H, Rao MS, Magnus T: Cytoplasmic translocation of Olig2 in adult glial progenitors marks the generation of reactive astrocytes following autoimmune inflammation. Exp Neurol; 2006 Oct;201(2):349-58
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic translocation of Olig2 in adult glial progenitors marks the generation of reactive astrocytes following autoimmune inflammation.
  • Following inflammatory insults to the adult CNS, formation of an astroglial scar often impedes functional repair.
  • Together, these data ascribe a pivotal role to Olig2+ glial precursor cells in the adult CNS, linking autoimmune inflammation and glial scar formation.
  • [MeSH-minor] Animals. Antigens / genetics. Antigens / metabolism. Cell Differentiation / drug effects. Cytoplasm / metabolism. Encephalomyelitis, Autoimmune, Experimental / immunology. Encephalomyelitis, Autoimmune, Experimental / metabolism. Encephalomyelitis, Autoimmune, Experimental / pathology. Glial Fibrillary Acidic Protein / genetics. Glial Fibrillary Acidic Protein / metabolism. Immunohistochemistry. Interferon-gamma / pharmacology. Mice. Mice, Inbred C57BL. Microglia / cytology. Microglia / metabolism. Microscopy, Fluorescence. Proteoglycans / genetics. Proteoglycans / metabolism. RNA / genetics. RNA / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Necrosis Factor-alpha / pharmacology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16814281.001).
  • [ISSN] 0014-4886
  • [Journal-full-title] Experimental neurology
  • [ISO-abbreviation] Exp. Neurol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Glial Fibrillary Acidic Protein; 0 / Nerve Tissue Proteins; 0 / Olig2 protein, mouse; 0 / Proteoglycans; 0 / Tumor Necrosis Factor-alpha; 0 / chondroitin sulfate proteoglycan 4; 63231-63-0 / RNA; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


80. Rivera AL, Pelloski CE: Diagnostic and prognostic molecular markers in common adult gliomas. Expert Rev Mol Diagn; 2010 Jul;10(5):637-49

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic molecular markers in common adult gliomas.
  • The majority of primary CNS tumors in adults are comprised of gliomas (astrocytomas, oligodendrogliomas and ependymomas).
  • The diagnosis has historically been based on the histologic appearance of these tumors.
  • In this article, we summarize the findings of important, published biomarker studies in adult gliomas and provide an overview of the practical uses of these markers in the clinical setting, as well as the current understanding of molecular gliomagenesis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy
  • [MeSH-minor] Adult. Clinical Trials as Topic. Gene Expression Profiling. Humans. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629512.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


81. Alameda F, Lloreta J, Ariza A, Salido M, Espinet B, Baro T, Garcia-Fructoso G, Galito E, Munne A, Cruz Sanchez FF, Sole F, Serrano S: Primitive neuroectodermal tumor of the central nervous system with glial differentiation: a FISH study of an adult case. Clin Neuropathol; 2007 Jan-Feb;26(1):12-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumor of the central nervous system with glial differentiation: a FISH study of an adult case.
  • Primitive neuroectodermal tumors (PNETs) of the central nervous system (CNS), a rare occurrence in adults, may show glial differentiation and can be misinterpreted as pure astrocytic neoplasms.
  • Few fluorescence in situ hybridization (FISH) studies have been carried out on these tumors; isochromosome 17q was found to be the major chromosomal abnormality.
  • We present the case of an adult in which we performed a FISH study of both the glial and neuronal components.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Chromosomes, Human, Pair 17 / genetics. Neuroectodermal Tumors, Primitive / genetics. Neuroectodermal Tumors, Primitive / pathology. Trisomy / genetics
  • [MeSH-minor] Adult. Humans. In Situ Hybridization, Fluorescence. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290931.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


82. Nasonkin I, Mahairaki V, Xu L, Hatfield G, Cummings BJ, Eberhart C, Ryugo DK, Maric D, Bar E, Koliatsos VE: Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum. Stem Cells; 2009 Oct;27(10):2414-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum.
  • Human embryonic stem cells (HESCs) are a rich source of neural precursors (NPs) for grafting, but have been questioned for their tendency to form tumors.
  • Here we studied the ability of HESC-derived NP grafts optimized for cell number and differentiation stage prior to transplantation, to survive and stably differentiate and integrate in the basal forebrain (neostriatum) of young adult nude rats over long periods of time (6 months).
  • Our findings demonstrate the long-term ability of noggin-derived human NPs to structurally integrate tumor-free into the mature mammalian forebrain, while maintaining some cell fate plasticity that is strongly influenced by particular central nervous system (CNS) niches.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cereb Cortex. 2000 Aug;10(8):729-47 [10920046.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16707-12 [18922775.001]
  • [Cites] Neuron. 2000 Dec;28(3):713-26 [11163261.001]
  • [Cites] Development. 2001 Oct;128(19):3759-71 [11585802.001]
  • [Cites] Nat Biotechnol. 2001 Dec;19(12):1129-33 [11731781.001]
  • [Cites] Nat Rev Neurosci. 2002 Apr;3(4):271-80 [11967557.001]
  • [Cites] Neuron. 2002 Aug 29;35(5):865-75 [12372282.001]
  • [Cites] J Neurosci. 2003 Jan 1;23(1):167-74 [12514213.001]
  • [Cites] BMC Neurosci. 2001;2:9 [11399205.001]
  • [Cites] J Cell Biol. 2003 Jun 9;161(5):911-21 [12796477.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):417-24 [12849120.001]
  • [Cites] Stem Cells. 2003;21(5):521-6 [12968106.001]
  • [Cites] BMC Neurosci. 2003 Oct 22;4:27 [14572319.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12543-8 [15310843.001]
  • [Cites] Neuroscience. 1986 Oct;19(2):465-93 [3022187.001]
  • [Cites] Nature. 1990 Oct 11;347(6293):556-8 [1699131.001]
  • [Cites] Prog Brain Res. 1990;82:391-9 [1705355.001]
  • [Cites] Brain Res. 1994 Dec 30;668(1-2):211-9 [7704606.001]
  • [Cites] Dev Biol. 1995 Apr;168(2):342-57 [7729574.001]
  • [Cites] Exp Neurol. 1996 Jan;137(1):15-25 [8566206.001]
  • [Cites] Mech Dev. 1996 Sep;59(1):89-102 [8892235.001]
  • [Cites] J Neurosci. 1997 Aug 1;17(15):5858-67 [9221783.001]
  • [Cites] Nature. 1997 Dec 18-25;390(6661):680-3 [9414159.001]
  • [Cites] Genes Dev. 1998 May 15;12(10):1438-52 [9585504.001]
  • [Cites] Stem Cells. 2004;22(6):925-40 [15536184.001]
  • [Cites] Nat Biotechnol. 2005 Feb;23(2):215-21 [15685164.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2475-85 [15743839.001]
  • [Cites] Nat Biotechnol. 2005 May;23(5):601-6 [15852001.001]
  • [Cites] J Neurosci. 2005 May 11;25(19):4694-705 [15888645.001]
  • [Cites] Stem Cells Dev. 2005 Jun;14(3):266-9 [15969621.001]
  • [Cites] J Neurosci. 2005 Sep 21;25(38):8714-24 [16177041.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14069-74 [16172374.001]
  • [Cites] Stem Cells. 2005 Oct;23(9):1234-41 [16002783.001]
  • [Cites] Stem Cells. 2005 Oct;23(9):1242-50 [16210408.001]
  • [Cites] Neuron. 2006 Jan 5;49(1):41-53 [16387638.001]
  • [Cites] Neuron. 2006 Jan 5;49(1):55-66 [16387639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1319-24 [16432194.001]
  • [Cites] Stem Cells. 2006 Jan;24(1):125-38 [16100006.001]
  • [Cites] Stem Cells Dev. 2006 Apr;15(2):254-9 [16646671.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1583-93 [16543488.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1433-40 [16556709.001]
  • [Cites] Exp Neurol. 2006 Oct;201(2):525-9 [16806174.001]
  • [Cites] Curr Opin Genet Dev. 2006 Oct;16(5):455-62 [16920351.001]
  • [Cites] Transplantation. 2006 Oct 15;82(7):865-75 [17038899.001]
  • [Cites] Eur J Neurosci. 2006 Oct;24(7):1885-96 [17067292.001]
  • [Cites] Dev Cell. 2006 Dec;11(6):831-44 [17141158.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):59-69, viii-ix [17244554.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):411-8 [17038668.001]
  • [Cites] J Neurosci. 2007 Feb 21;27(8):1836-52 [17314281.001]
  • [Cites] Neurobiol Aging. 2007 Aug;28(8):1148-62 [16859812.001]
  • [Cites] Glia. 2007 Aug 15;55(11):1156-68 [17597119.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):1931-9 [17478583.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e39 [17298165.001]
  • [Cites] J Neurosci. 2007 Nov 21;27(47):12787-96 [18032650.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] Expert Opin Biol Ther. 2008 Feb;8(2):137-41 [18194070.001]
  • [Cites] Curr Protoc Neurosci. 2005 Nov;Chapter 3:Unit 3.18 [18428621.001]
  • [Cites] EMBO J. 2000 Oct 16;19(20):5460-72 [11032813.001]
  • (PMID = 19609935.001).
  • [ISSN] 1549-4918
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / DC000232; United States / NINDS NIH HHS / NS / R01 NS045140; United States / NINDS NIH HHS / NS / NS45140-03; United States / NEI NIH HHS / EY / P30 EY001765; United States / NIDCD NIH HHS / DC / DC000232-23; United States / NIDCD NIH HHS / DC / R01 DC000232-23; United States / NIDCD NIH HHS / DC / DC005211-089002; United States / NIDCD NIH HHS / DC / R01 DC000232; United States / NIDCD NIH HHS / DC / P30 DC005211; United States / NINDS NIH HHS / NS / R01 NS045140-03; United States / NEI NIH HHS / EY / EY01765; United States / NINDS NIH HHS / NS / NS045140-03; United States / NIDCD NIH HHS / DC / P30 DC005211-089002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Phosphoproteins; 148294-77-3 / noggin protein
  • [Other-IDs] NLM/ NIHMS193803; NLM/ PMC2906132
  •  go-up   go-down


83. Sgubin D, Aztiria E, Perin A, Longatti P, Leanza G: Activation of endogenous neural stem cells in the adult human brain following subarachnoid hemorrhage. J Neurosci Res; 2007 Jun;85(8):1647-55
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of endogenous neural stem cells in the adult human brain following subarachnoid hemorrhage.
  • In the adult human brain, the presence of neural stem cells has been documented in the subgranular layer of the dentate gyrus of the hippocampus and in the subventricular zone of the lateral ventricles.
  • Ten cerebral samples from both SAH and control patients obtained, respectively, during aneurysm clipping and deep brain tumor removal were analyzed by reverse transcription followed by polymerase chain reaction (RT-PCR) and/or immunohistochemistry (IHC).
  • In tissue specimens from SAH patients, RT-PCR and IHC revealed the expression of a variety of markers consistent with CNS progenitor cells, including nestin, vimentin, SOX-2, and Musashi1 and -2.
  • Thus, activation of neural progenitor cell proliferation may occur in adult human brain following subarachnoid hemorrhage, possibly contributing to the promotion of spontaneous recovery, in this pathological condition.
  • [MeSH-minor] Adult. Aged. Aneurysm, Ruptured / complications. Biomarkers / metabolism. Cell Proliferation. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Intracranial Aneurysm / complications. Male. Microscopy, Confocal. Microscopy, Fluorescence. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17455304.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


84. Schramm P, Xyda A, Klotz E, Tronnier V, Knauth M, Hartmann M: Dynamic CT perfusion imaging of intra-axial brain tumours: differentiation of high-grade gliomas from primary CNS lymphomas. Eur Radiol; 2010 Oct;20(10):2482-90
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic CT perfusion imaging of intra-axial brain tumours: differentiation of high-grade gliomas from primary CNS lymphomas.
  • We investigated if different brain tumor types can be distinguished from each other using Patlak analysis of PCT data.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / pathology. Glioma / diagnosis. Glioma / pathology. Lymphoma / diagnosis. Lymphoma / pathology. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Biopsy. Brain / pathology. Cerebrovascular Circulation. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Perfusion

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 May;21(5):891-9 [10815665.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Stroke. 2001 Feb;32(2):431-7 [11157178.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):193-200 [11465400.001]
  • [Cites] Eur Radiol. 2002 Feb;12(2):329-40 [11870430.001]
  • [Cites] J Magn Reson Imaging. 2002 Mar;15(3):233-40 [11891967.001]
  • [Cites] Neurosci Lett. 2003 Feb 27;338(2):119-22 [12566167.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 May;25(5):746-55 [15140713.001]
  • [Cites] Acad Radiol. 2004 May;11(5):573-82 [15147622.001]
  • [Cites] Stroke. 2004 Jul;35(7):1652-8 [15155964.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Mar;21(3):462-70 [10730636.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1363-80 [10751361.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Mayo Clin Proc. 1987 Jun;62(6):450-9 [3553757.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Jul-Aug;13(4):1207-13 [1636538.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;119(1):7-27 [1400570.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4564-8 [8062241.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):9-19 [7541613.001]
  • [Cites] Radiology. 1996 Mar;198(3):813-8 [8628876.001]
  • [Cites] J Neurooncol. 1997 May;32(3):253-65 [9049887.001]
  • [Cites] AJR Am J Roentgenol. 1998 Oct;171(4):941-9 [9762973.001]
  • [Cites] Eur J Radiol. 1999 Jun;30(3):170-84 [10452715.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] J Magn Reson Imaging. 2006 Aug;24(2):288-96 [16795091.001]
  • [Cites] Neuroradiology. 2006 Oct;48(10):773-81 [16937146.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2729-35 [17363594.001]
  • [Cites] Neuroradiology. 2007 Jul;49 Suppl 1:S35-45 [17665157.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Apr;29(4):694-700 [18202239.001]
  • (PMID = 20495977.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2940017
  •  go-up   go-down


85. Varghese M, Olstorn H, Berg-Johnsen J, Moe MC, Murrell W, Langmoen IA: Isolation of human multipotent neural progenitors from adult filum terminale. Stem Cells Dev; 2009 May;18(4):603-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation of human multipotent neural progenitors from adult filum terminale.
  • Stem cells have been isolated from several CNS regions, including the spinal cord.
  • We show for the first time that progenitor cells exhibiting the hallmarks of stem cells can be isolated from adult human filum terminale (FTNPs).
  • Significantly, no tumor formation or aberrant cell morphology was seen in or adjacent to the graft area.
  • Thus, filum terminale provides a novel source of adult human neural progenitor cells that develop into functional neurons with possible clinical applications.
  • [MeSH-minor] Adult. Animals. Biopsy. Cell Differentiation / physiology. Cell Proliferation. Cells, Cultured. Child. Humans. Membrane Potentials / physiology. Middle Aged. Patch-Clamp Techniques. Rats. Stem Cell Transplantation. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652547.001).
  • [ISSN] 1557-8534
  • [Journal-full-title] Stem cells and development
  • [ISO-abbreviation] Stem Cells Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


86. Butovsky O, Ziv Y, Schwartz A, Landa G, Talpalar AE, Pluchino S, Martino G, Schwartz M: Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol Cell Neurosci; 2006 Jan;31(1):149-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells.
  • Cell renewal in the adult central nervous system (CNS) is limited, and is blocked in inflammatory brain conditions.
  • We show that both neurogenesis and oligodendrogenesis of adult neural progenitor cells in mice are blocked by inflammation-associated (endotoxin-activated) microglia, but induced by microglia activated by cytokines (IL-4 or low level of IFN-gamma) associated with T-helper cells.
  • Blockage was correlated with up-regulation of microglial production of tumor necrosis factor-alpha.
  • It thus appears that microglial phenotype critically affects their ability to support or impair cell renewal from adult stem cell.


87. Xiong NX, Zhao HY, Zhang FC, He ZQ: Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor. Neurosci Bull; 2007 Jan;23(1):41-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor.
  • OBJECTIVE: Nogo-A is an axon regeneration inhibitor, and its function in central nervous system (CNS) is still unknown.
  • The present study is to explore the relationship between the expression of Nogo-A and the malignancy of oligodendroglial tumors in patients.
  • METHODS: Tumor tissue samples with different malignancy grade were obtained from the hospitals.
  • The samples used for detection had been diagnosed as oligodendroglial tumors (oligodendroglioma or anaplastic oligodendroglioma).
  • The correlation test between the Nogo-A expression and the morphological changes (the percentages of atypical cells and mitotic cells in the tumors) related to the malignancy of tumor tissues was performed.
  • RESULTS: There was significant negative correlation between the Nogo-A expression and the morphological change of tumor tissues according to immunohistochemistry.
  • CONCLUSION: Nogo-A expression was negatively correlated with the malignancy grade of oligodendroglial tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Myelin Proteins / metabolism. Oligodendroglioma / diagnosis. Oligodendroglioma / metabolism
  • [MeSH-minor] Adult. Down-Regulation / physiology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mitotic Index. Neoplasm Invasiveness / diagnosis. Nogo Proteins. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2002 May 1;22(9):3553-67 [11978832.001]
  • [Cites] J Neurosci. 2003 Jul 2;23 (13):5393-406 [12843238.001]
  • [Cites] Oncogene. 2001 Jul 5;20(30):3929-36 [11494121.001]
  • [Cites] J Mol Neurosci. 2005;25(1):1-6 [15781961.001]
  • [Cites] J Cell Physiol. 2003 Aug;196 (2):312-8 [12811824.001]
  • [Cites] Nature. 2000 Jan 27;403(6768):434-9 [10667796.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19280-5 [12639960.001]
  • [Cites] Nature. 2000 Jan 27;403(6768):439-44 [10667797.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):149-58 [9426071.001]
  • [Cites] J Neurochem. 2004 Sep;90(5):1156-62 [15312170.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1390-9 [12618765.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5736-46 [11126360.001]
  • [Cites] Biochem J. 2005 Oct 15;391(Pt 2):433-40 [16095439.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):2977-87 [15021917.001]
  • [Cites] Apoptosis. 2003 Jan;8(1):5-9 [12510146.001]
  • (PMID = 17592524.001).
  • [ISSN] 1673-7067
  • [Journal-full-title] Neuroscience bulletin
  • [ISO-abbreviation] Neurosci Bull
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Myelin Proteins; 0 / Nogo Proteins; 0 / RTN4 protein, human
  •  go-up   go-down


88. Makuria AT, Rushing EJ, McGrail KM, Hartmann DP, Azumi N, Ozdemirli M: Atypical teratoid rhabdoid tumor (AT/RT) in adults: review of four cases. J Neurooncol; 2008 Jul;88(3):321-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid rhabdoid tumor (AT/RT) in adults: review of four cases.
  • Atypical teratoid/rhabdoid (AT/RT) tumor is a rare, highly malignant tumor of the central nervous system (CNS) most commonly found in children less than 5 years of age.
  • Since its histological appearance can be confused with other tumors, especially in adults, separating AT/RT from other neoplasms may be difficult.
  • Radiographically, two tumors were localized in the right fronto-parietal region, one was frontal and the other was found in the left temporal lobe.
  • Immunohistochemical staining showed that the tumor cells were positive for vimentin and reacted variably for keratin, epithelial membrane antigen (EMA), synaptophysin, neurofilament protein, CD34, and smooth muscle actin (SMA).
  • In adult examples of AT/RT, the diagnosis requires a high index of suspicion, with early tissue diagnosis and a low threshold for investigation with INI1 immunohistochemistry to differentiate this entity from other morphologically similar tumors.
  • Although the prognosis is dismal in pediatric population, long term survival is possible in adult AT/RT cases after surgery and adjuvant radiotherapy and chemotherapy.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Rhabdoid Tumor / metabolism. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adult. Chromosomal Proteins, Non-Histone / metabolism. DNA-Binding Proteins / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. SMARCB1 Protein. Transcription Factors / metabolism

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1981 Jul;12(7):646-57 [7275104.001]
  • [Cites] Semin Cell Dev Biol. 1999 Apr;10 (2):189-95 [10441072.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):49-56 [11451202.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):121-6 [12622450.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):951-8 [15761491.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2278-92 [9694794.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):729-37 [8391222.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2877-84 [15254056.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):79-82 [16443951.001]
  • [Cites] Can J Neurol Sci. 1996 Nov;23(4):257-63 [8951203.001]
  • [Cites] Neuroradiology. 2000 May;42(5):363-7 [10872158.001]
  • [Cites] Pathol Int. 1999 Dec;49(12):1114-8 [10632935.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3461-7 [12429635.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] J Neurooncol. 2005 Sep;74(3):311-9 [16132523.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Am J Surg Pathol. 1994 Oct;18(10):1010-29 [8092393.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12311-5 [10535918.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6171-7 [11085541.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):223-7 [9024522.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):23-8 [15779233.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Acta Neurochir (Wien). 2004 Sep;146(9):1033-8; discussion 1038 [15340816.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):247 [10477033.001]
  • [Cites] Neuropathology. 2002 Dec;22(4):252-60 [12564764.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Pediatr Radiol. 2006 Feb;36(2):126-32 [16341528.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):323-8 [11782395.001]
  • [Cites] Cancer. 1978 May;41(5):1937-48 [206343.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):156-62 [11230702.001]
  • [Cites] Cancer Res. 2004 May 15;64(10 ):3406-13 [15150092.001]
  • [Cites] Neuropathology. 2006 Feb;26(1):57-61 [16521480.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):49-55 [17377740.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):74-9 [9892189.001]
  • [Cites] Neurol India. 2003 Jun;51(2):273-4 [14571026.001]
  • [Cites] Ultrastruct Pathol. 1997 Jul-Aug;21(4):361-8 [9206001.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2002-6 [7801128.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7748-53 [10884406.001]
  • [Cites] Mol Cell. 1999 Feb;3(2):247-53 [10078207.001]
  • (PMID = 18369529.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 Protein; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


89. Anclair M, Hovén E, Lannering B, Boman KK: Parental fears following their child's brain tumor diagnosis and treatment. J Pediatr Oncol Nurs; 2009 Mar-Apr;26(2):68-74
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parental fears following their child's brain tumor diagnosis and treatment.
  • The objective of this study is to portray the illness-related threats experienced by parents of children after the diagnosis of central nervous system (CNS) tumor.
  • Parents were asked to rate the extent to which they experienced a set of specific fears related to their child's brain tumor and its treatment.
  • Outcomes for parents of CNS tumor patients (n = 82) were compared with those of reference parents of patients treated for acute lymphoblastic leukemia (n = 208).
  • The fears about an illness recurrence and the late effects of treatment were most prominent among parents of CNS tumor patients.
  • For 7 out of 11 kinds of fear, parents of CNS tumor patients expressed a stronger fear than the reference group.
  • More than a quarter of the parents of children treated for CNS tumors feared a complete decline of the child.
  • Parents of CNS tumor patients experience relatively heightened cancer related fears in several domains.
  • [MeSH-major] Brain Neoplasms / psychology. Fear. Parents / psychology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cross-Sectional Studies. Humans. Infant. Infant, Newborn

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190177.001).
  • [ISSN] 1043-4542
  • [Journal-full-title] Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses
  • [ISO-abbreviation] J Pediatr Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


90. Guan YG, Wang TH, Ni W, Li L, Lu YC, Gao ZY: [Distribution of Fas and FasL in the central nervous system of adult rhesus]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 May;36(3):322-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distribution of Fas and FasL in the central nervous system of adult rhesus].
  • OBJECTIVE: To investigate the distribution of Fas and FasL in the CNS of adult rhesus.
  • CONCLUSION: The distribution profiles of Fas and FasL in various areas of CNS indicate that they may fill some roles in the immune and physical function of the aforesaid anatomic
  • [MeSH-major] Antigens, CD95 / metabolism. Brain Chemistry. Membrane Glycoproteins / metabolism. Tumor Necrosis Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address: